<SEC-DOCUMENT>0001641172-25-003854.txt : 20250411
<SEC-HEADER>0001641172-25-003854.hdr.sgml : 20250411
<ACCEPTANCE-DATETIME>20250411164015
ACCESSION NUMBER:		0001641172-25-003854
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20250411
DATE AS OF CHANGE:		20250411

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286385
		FILM NUMBER:		25832708

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>form424b4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"> Filed pursuant to Rule 424(b)(4) </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right">Registration No. 333-286385</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5pt; text-align: left"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>467,393 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>434,784 Shares of Common Stock Issuable Upon the
Exercise of Outstanding 2025 Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>32,609 Shares of Common Stock Issuable Upon the
Exercise of 2025 Placement Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b4_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>LIXTE BIOTECHNOLOGY HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Common Stock</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to this prospectus, the selling stockholders
identified herein are offering on a resale basis 467,393 shares of our common stock, par value $0.0001 per share, issuable upon exercise
of certain common stock warrants (the &ldquo;2025 Warrants&rdquo; and the &ldquo;2025 Placement Agent Warrants&rdquo;, as defined below).
We issued the 2025 Warrants in an exempt private offering (the &ldquo;Private Placement&rdquo;) pursuant to a securities purchase agreement,
dated February 11, 2025 (the &ldquo;Purchase Agreement&rdquo;) with the selling stockholders. We will not receive any of the proceeds
from the sale by the selling stockholders of the common stock. However, upon exercise of the 2025 Warrants or the 2025 Placement Agent
Warrants by payments of cash, we will receive the respective aggregate exercise prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The selling stockholders may sell or otherwise dispose
of the common stock covered by this prospectus in a number of different ways and at varying prices. We provide more information about
how the selling stockholders may sell or otherwise dispose of the common stock covered by this prospectus in the section entitled &ldquo;Plan
of Distribution&rdquo;. Discounts, concessions, commissions and similar selling expenses attributable to the sale of common stock covered
by this prospectus will be borne by the selling stockholders. We will pay all expenses (other than discounts, concessions, commissions
and similar selling expenses) relating to the registration of the common stock with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You should carefully read this prospectus, together
with the documents we incorporate by reference, before you invest in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is listed on The Nasdaq Capital
Market under the symbol &ldquo;LIXT&rdquo;. On April 2, 2025, the last reported sale price for our common stock was $1.22 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in common stock involves risk. Please
read carefully the section entitled </B>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B>&rdquo;
</FONT><B>beginning on page 13 of this prospectus or incorporated by reference.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The date of this prospectus is April 11,
2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Page No.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 0.5in; text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#a_004">RISK FACTORS</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">SELECTED HISTORICAL FINANCIAL DATA</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_013"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#a_014">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">31</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should rely only on the information
contained in or incorporated by reference into this prospectus and in any free writing prospectus. We have not and the selling stockholders
have not authorized anyone to provide you with information different from that contained in this prospectus., The sale of our securities
will only be made in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the
date of this prospectus, and any information we have incorporated by reference is accurate only as of the date of the document incorporated
by reference, regardless of the time of delivery of this prospectus or any sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither we nor the selling stockholders
have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus
must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus
outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We own or have rights to trademarks
or trade names that we use in connection with the operation of our business, including our corporate names, logos and website names.
In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that protect the content of our products.
This prospectus may also contain trademarks, service marks and trade names of other companies, which are the property of their respective
owners. Our use or display of third parties&rsquo; trademarks, service marks, trade names or products in this prospectus is not intended
to, and should not be read to, imply a relationship with or endorsement or sponsorship of us. Solely for convenience, some of the copyrights,
trade names and trademarks referred to in this prospectus are listed without their &copy;, &reg; and <SUP>TM</SUP> symbols, but we will
assert, to the fullest extent under applicable law, our rights to our copyrights, trade names and trademarks. All other trademarks are
the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>The following summary highlights
information contained or incorporated by reference elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus,
including our consolidated financial statements and the related notes and other documents incorporated by reference herein, as well as
the information under the caption &ldquo;Risk Factors&rdquo; herein and under similar headings in the other documents that are incorporated
by reference into this prospectus including documents that are filed after the date hereof. Some of the statements in this prospectus
constitute forward-looking statements that involve risks and uncertainties. See &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;.
Our actual results could differ materially from those anticipated in such forward-looking statements as a result of certain factors,
including those discussed in the &ldquo;Risk Factors&rdquo; and other sections included in or incorporated by reference herein. In this
prospectus, unless otherwise stated or the context otherwise requires, references to &ldquo;Lixte&rdquo;, the &ldquo;Company&rdquo;,
&ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, or similar references mean Lixte Biotechnology Holdings, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. Our product
pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic agents, radiation, immune
checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic potential
for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as
LB-100, which has been shown to have clinical anti-cancer activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that the mechanism
by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical use. LB-100 is currently being
tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer, and Advanced Soft Tissue
Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers
of neural tissue. LB-100 has also been shown to enhance the effectiveness of commonly used anti-cancer drugs in animal models of melanoma,
breast cancer and sarcoma. The enhancement of anti-cancer activity of these anti-cancer drugs occurs at doses of LB-100 that do not significantly
increase toxicity in animals. It is therefore hoped that, when combined with standard anti-cancer regimens against many tumor types,
LB-100 will improve therapeutic benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a compound moves through the
FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment at each stage. As the potential
effectiveness of LB-100 has been documented at the clinical trial level, we have allocated resources to expand the breadth and depth
of its patent portfolio. Our approach has been to operate with a minimum of overhead, moving compounds forward as efficiently and inexpensively
as possible, and to raise funds to support each of these stages as certain milestones are reached. Our longer-term objective is to secure
one or more strategic partnerships or licensing agreements with pharmaceutical companies with major programs in cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our activities are subject to
significant risks and uncertainties, including the need for additional capital. We have not yet commenced any revenue-generating operations,
does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant
compensation, and is dependent on periodic access to equity capital to fund its operating requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Description of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Most cancer patients are treated
with either chemotherapy or immunotherapy or both. These therapies often have limited benefit and there is a high unmet medical need
to enhance their effects. In many preclinical models we have shown that LB-100 enhances the effect of both chemotherapy and Immunotherapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="form424b4_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LB-100, a small molecule potent
inhibitor of PP2A, was designed and developed by us. Numerous preclinical studies have documented that LB-100 potentiates most if not
all anti-cancer drugs that damage DNA. LB-100 is not associated with any increase in cytotoxicity when given with cytotoxic drugs. This
synergy involves transient interruption of several DNA damage repair pathways by LB-100 and an increase in cell division rate. LB-100
has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In its initial Phase 1 clinical
trial, LB-100 given alone daily for 3 days was non-toxic, except for a transient increase in serum creatinine believed to be caused by
inhibition of PP2A in the renal tubules. In the Phase 1 clinical trial, the Maximum Tolerated Dose (&ldquo;MTD&rdquo;) was 2.33mg/m2
daily for 3 days every 3 weeks. Of the 25 patients with heavily-treated advanced solid tumors with measurable disease, 3 patients had
stable disease for 2 cycles, 3 patients had stable disease for 4 cycles, and 3 patients had stable disease for 6 cycles. One patient
with pancreatic cancer had a partial response after 12 cycles lasting 534 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Low doses of LB-100 have now
been shown to enhance immune checkpoint inhibition (&ldquo;ICI&rdquo;) by several different mechanisms affecting the tumor compartment
and immune T-cell compartment. LB-100 increases CD8+T-cell infiltration and CD8-Treg ratio, CD8+T-cell proliferation, and cytokine production
induces microsatellite instability, neoantigen production and immune responsiveness, converting immunologically &ldquo;cold&rdquo; to
&ldquo;hot&rdquo; cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b4_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ovarian clear cell carcinoma
patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with immune checkpoint inhibitors,
were recently found to have markedly longer survival than patients without the mutation in their cancers. Retrospective reviews of patients
with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated patients with a PPP2R1A mutation
in their tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b4_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on the observations in
ovarian clear cell carcinoma, we have initiated a clinical trial in this disease combining LB-100 with a monoclonal antibody blocking
PD-1, a protein found on T-cells (NCT06065462).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Given these preclinical and clinical
observations, it is likely that LB-100 may be a general way to enhance immunotherapy responses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b4_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The research on the LB-100 series
was initiated in 2006 under a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with the National Institute of Neurologic
Disorders and Stroke or NINDS of the National Institutes of Health or NIH dated March 22, 2006 that was subsequently extended through
a series of amendments until it terminated on April 1, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have also designed and developed
the LB-200 series, which consists of histone deacetylase inhibitors (HDACi). LB-200 has not advanced to the clinical stage and would
require additional capital to fund further development. Accordingly, because of our focus on the clinical development of LB-100 and analogs
for cancer therapy as described below in more detail, we have decided not to actively pursue the preclinical development of our LB-200
series of compounds at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Clinical Trial Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">Spanish
Sarcoma Group Collaboration Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Effective
July 31, 2019, we entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group
(Grupo Espa&ntilde;ol de Investigaci&oacute;n en Sarcomas or &ldquo;GEIS&rdquo;), Madrid, Spain, to carry out a study entitled &ldquo;Randomized
phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma&rdquo;. The purpose of
this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with doxorubicin in soft tissue
sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&ldquo;ASTS&rdquo;). Doxorubicin
alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. We agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to
provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over a period of
two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose
of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion of
the study assumes a median progression-free survival (&ldquo;PFS&rdquo;), no evidence of disease progression or death from any cause)
of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a
statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October
13, 2022, we announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&ntilde;ola de Medicamentos y Productos
Sanitarios or &ldquo;AEMPS&rdquo;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin,
versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). Consequently, this clinical
trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026. In April 2023,
GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&oacute;n Jim&eacute;nez D&iacute;az University
Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment phase of the Phase 1b portion of the protocol
was completed during the quarter ended September 30, 2024. We expect to have data on toxicity and preliminary efficacy from this portion
of the clinical trial during the quarter ending December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, we entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved us of the
financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration Agreement of approximately
$3,095,000. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical Research Support Agreement
Relating to Small Cell Lung Cancer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had executed a Clinical Research
Support Agreement with the City of Hope National Medical Center to carry out a Phase 1b clinical trial of LB-100 combined with an FDA-approved
standard regiment for treatment of untreated extensive-stage disease small cell lung cancer. The clinical trial was initiated on March
9, 2021. However, due to the lack of patient accrual, the Company provided notice to the City of Hope National Medical Center of our
intent to terminate the Clinical Research Support Agreement effective as of July 8, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">MD Anderson Cancer Center Clinical
Trial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 20, 2023, we announced
an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1
(&ldquo;PD-1&rdquo;) blocking antibody of GSK plc (&ldquo;GSK&rdquo;), dostarlimab-gxly, may enhance the effectiveness of immunotherapy
in the treatment of ovarian clear cell carcinoma (&ldquo;OCCC&rdquo;). The clinical trial is being sponsored by The University of Texas
MD Anderson Cancer Center (&ldquo;MD Anderson&rdquo;) and is being conducted at The University of Texas &ndash; MD Anderson Cancer Center.
We are providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the clinical trial. On January 29, 2024, we announced
the entry of the first patient into this clinical trial. We currently expect that this clinical trial will be completed by December 31,
2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 25, 2025, we announced
that we had added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in
a clinical trial combining the Company&rsquo;s proprietary compound LB-100 with GSK&rsquo;s dostarlimab to treat ovarian clear cell cancer.
Patient recruitment is underway, and the first patient has been dosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Netherlands Cancer Institute
Clinical Trial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective June 10, 2024, we entered
into a Clinical Trial Agreement with the Netherlands Cancer Institute (&ldquo;NKI&rdquo;) to conduct a Phase 1b clinical trial of the
Company&rsquo;s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F.
Hoffman-La Roche Ltd. (&ldquo;Roche&rdquo;), for patients with microsatellite stable metastatic colon cancer. Under the agreement, we
will provide our lead clinical compound, LB-100, and under a separate agreement between NKI and Roche, Roche will provide atezolizumab
and financial support for the clinical trial. We have no obligation to and will not provide any reimbursement of clinical trial costs.
Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at NKI&rsquo;s site
in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The agreement
provides for the protection of the respective intellectual property rights of each of Lixte, NKI and Roche.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Phase 1b clinical trial
will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment of patients with metastatic
microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can enhance the body&rsquo;s immune
response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness of anticancer drugs in
killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals in tumor cells expressing
the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic colorectal cancer, as
cancer cells with heightened stress signals are more vulnerable to immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This study comprises a dose escalation
phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended Phase 2 dose (RP2D) of LB-100
when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate the preliminary efficacy, safety,
tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical trial opened in August 2024 with
the enrollment of the first patient. Patient accrual is expected to take up to 24 months, with a maximum of 37 patients with advanced
colorectal cancer to be enrolled in this study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The principal investigator of
the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious Adverse Events (&ldquo;SAEs&rdquo;)
observed in the clinical trial that was launched in August 2024. The Investigational Review Board (IRB) of the Netherlands Cancer Institute
has requested additional information with respect to these SAEs and the study has been paused for enrollment until the IRB&rsquo;s questions
have been, as more fully discussed at &ldquo;Item 7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations &ndash; Specific Risks Associated with the Company&rsquo;s Business Activities &ndash; Serious Adverse Events&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">National Cancer Institute Pharmacologic
Clinical Trial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2019, the National Cancer
Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial. This study was being conducted and funded by the NCI under
a Cooperative Research and Development Agreement, with the Company being required to provide the LB-100 clinical compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Primary malignant brain tumors
(gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been the mainstay of therapy
of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained by the addition of one
or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal models of GBM, the
Company&rsquo;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation, temozolomide chemotherapy
treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment in the clinic. Although
LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human cancers arising outside
the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially useful for GBM
treatment do not enter the brain in amounts necessary for anti-cancer action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The NCI study was designed to
determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one or more tumors received
one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100 present and to determine
whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its molecular target. As a result
of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient to provide a sound rationale
for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs. Blood
and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100. Results of the investigation
demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative methods of drug delivery
will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme and other aggressive
brain tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Patent and License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">National Institute of Health</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective February 23, 2024,
we entered into a Patent License Agreement (the &ldquo;License Agreement&rdquo;) with the National Institute of Neurological Disorders
and Stroke (&ldquo;NINDS&rdquo;) and the National Cancer Institute (&ldquo;NCI&rdquo;), each an institute or center of the National Institute
of Health (&ldquo;NIH&rdquo;). Pursuant to the License Agreement, we have licensed exclusively NIH&rsquo;s intellectual property rights
claimed for a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) subject invention co-developed with the Company, and
the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs.
The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer. The License
Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis, until the expiration of the last-to-expire
valid claim of the jointly owned licensed patent rights in each such country in the licensed territory, unless sooner terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The License Agreement contemplates
that we will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive cancer centers) to initiate
clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be the subject of various regulatory
filings for marketing approval in applicable countries in the licensed territories. Subject to the receipt of marketing approval, we
would be expected to commercialize the licensed products in markets where regulatory approval has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Other Significant Agreements and Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Netherlands Cancer Institute</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 8, 2021, we entered
into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (&ldquo;NKI&rdquo;), one of the world&rsquo;s
leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, for a term of three
years. The Development Collaboration Agreement was subsequently modified by Amendment No. 1 thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Development Collaboration
Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues,
to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
We agreed to fund the preclinical study, at an approximate cost of 391,000 Euros and provide a sufficient supply of LB-100 to conduct
the preclinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 3, 2023, we entered
into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research activities, extends
the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000 Euros to the operating
budget being funded by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 4, 2024, we entered
into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment No. 2 and provided for a new study
term of one year and starts upon the dosing of the first patient in the clinical trial at a project cost of 100,000 Euros.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective as of June 15, 2022,
Dr. Ren&eacute; Bernards was appointed to our Board of Directors as an independent director. Dr. Bernards is a leader in the field of
molecular carcinogenesis and is employed by NKI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our intellectual property includes
proprietary know-how, proprietary methodologies and extensive clinical validation data and publications. To provide legal protection
of our intellectual property, we rely on a combination of patents, licenses, trade secrets, trademarks, confidentiality and non-disclosure
clauses and agreements, and other forms of intellectual property protection to define and protect our rights to our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products are expected to
be covered by our patents. These patents now cover sole rights to the composition and synthesis of our LB-100 series of drugs, which
is the Company&rsquo;s lead clinical compound in development. Lixte has filed patent applications covering the treatment of cancer with
LB-100. Lixte has also filed joint patent applications with the NIH and the Netherlands Cancer Institute for the treatment of cancer
using LB-100 in combination with other drugs like immune checkpoint inhibitors and WEE1 inhibitors (a class of drugs that target and
inhibit the WEE1 kinase enzyme that plays a crucial role in regulating cell division).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patent applications for the LB-100
series (oxabicycloheptanes and oxabicycloheptenes) have been filed in the United States and internationally under the Patent Cooperation
Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in the United States, Mexico, Australia,
Japan, China, Hong Kong, Canada, and by the European Patent Office</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We strive to protect and enhance
the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including
seeking, maintaining, and defending its patent rights, which are owned solely by our wholly-owned Delaware subsidiary, Lixte Biotechnology,
Inc., except in several instances jointly with one of many of our collaborators. We also rely on trade secrets relating to its proprietary
pipeline of product candidates and on know-how and continuing technological innovation to develop and strengthen its pipeline. We intend
to rely on regulatory protection afforded by regulatory agencies through data exclusivity, market exclusivity, and patent term extensions,
where available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success will depend in large
part on its ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions
and know-how related to its business; defend and enforce its patents; preserve the confidentiality of its trade secrets; and operate
without infringing valid and enforceable patents or proprietary rights of third parties. Our ability to stop third parties from making,
using, selling, offering to sell, or importing our technology may depend on the extent to which we have rights under valid and enforceable
licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may depend on cooperation
of the joint owners of our jointly owned patents and patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With respect to both our solely
and jointly owned intellectual property, we cannot be sure that patents will be granted on any of its pending patent applications or
on any patent applications filed solely or jointly by us in the future; we cannot be sure that any of our existing patents or any patents
that may be granted to us in the future will be commercially useful in protecting our intended commercial products or therapeutic methods;
and we cannot be sure that an agency or court would determine that the our solely or jointly owned patents are valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Nasdaq Compliance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, we announced
via Current Report on Form 8-K that we received a letter from the Listing Qualifications Department (the &ldquo;Staff&rdquo;) of the
Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) on August 19, 2024 indicating that we were not in compliance with the minimum stockholders&rsquo;
equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &ldquo;Stockholders&rsquo;
Equity Requirement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 3, 2024, we submitted
a plan to the Staff to regain compliance with the Stockholders&rsquo; Equity Requirement, which outlined our proposed initiatives to
regain compliance by raising equity capital through various registered equity offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 21, 2024, the Staff
provided notice (the &ldquo;Notice&rdquo;) to us that it had granted an extension through February 18, 2025 to regain compliance with
the Stockholders&rsquo; Equity Requirement, which required that we complete our capital raising initiatives and evidence compliance with
the Stockholders&rsquo; Equity Requirement through filing a Current Report on Form 8-K with the Securities and Exchange Commission providing
certain required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of February 18, 2025, we
had not regained compliance with the Stockholders&rsquo; Equity Requirement. Accordingly, on February 19, 2025, we received a Staff determination
letter from the Staff stating that we did not meet the terms of the extension because we did not complete our proposed financing initiatives
to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We timely requested a Hearing
before a Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;), which automatically stayed Nasdaq&rsquo;s suspension or delisting of our common
shares and warrants pending the Panel&rsquo;s decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant us
an additional extension through no later than August 18, 2025. However, there can be no assurances that the Hearings Panel will grant
us an extension of time to regain compliance, or that we will be able to regain compliance during an extension period. During the hearings
process our common shares and warrants will continue to trade on The Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to take reasonable
measures available to regain compliance under Nasdaq&rsquo;s listing rules and to remain listed on Nasdaq. However, there can be no assurances
that we will ultimately regain compliance with the Stockholders&rsquo; Equity Rule, or be able to maintain compliance with all other
applicable requirements for continued listing on Nasdaq. Our failure to meet these requirements may result in our securities being delisted
from Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were incorporated as a Delaware
Corporation on May 24, 2005 under the name SRKP7, Inc. On June 30, 2006, pursuant to a share exchange agreement, we acquired all of the
outstanding shares of Lixte Biotechnology, Inc. which then became a wholly owned subsidiary. On December 7, 2006, we changed our name
to Lixte Biotechnology Holdings, Inc. Effective September 26, 2023, Bastiaan van der Baan, a director of the Company since June 17, 2022,
replaced our founder, John S. Kovach, as President and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective
October 6, 2023, Mr. van der Baan was appointed as Chairman of our Board of Directors. Our common stock and Common Warrants are traded
on Nasdaq under the symbols &ldquo;LIXT&rdquo; and &ldquo;LIXTW&rdquo;, respectively. On June 2, 2023, we effected a one-for-ten reverse
split of our outstanding shares of common stock in order to remain in compliance with the $1.00 minimum closing bid price requirement
of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our principal address is 680
East Colorado Boulevard, Suite 180, Pasadena, CA 91101. Our telephone number is (631) 830-7092. We maintain a website at <U>https://lixte.com</U>.
The information contained on our website is not, and should not be interpreted to be, incorporated into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>July 2023 Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 20, 2023, we sold 583,334
shares of common stock at a price of $6.00 per share to an institutional investor and raised gross proceeds of approximately $3,500,000.
As part of this financing, we sold warrants to the institutional investor to purchase 583,334 shares of common stock (the &ldquo;2023
Warrants&rdquo;). The 2023 Warrants had an initial exercise price of $6.00 per share, were immediately exercisable upon issuance, and
expire five years thereafter on July 20, 2028. We also issued warrants to the placement agent to purchase 35,000 shares of common stock
at an exercise price of $6.60 per share and expiring on July 20, 2028 (the &ldquo;2023 Placement Agent Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The exercise prices of the warrants
issued to the institutional investor and to the placement agent are subject to customary adjustments for stock splits, stock dividends,
stock combinations, reclassifications, reorganizations, or similar events affecting our common stock. In addition, the warrants issued
to the institutional investor contain a &ldquo;fundamental transaction&rdquo; provision whereby in the event of a fundamental transaction
(including a sale or transfer of assets or ownership of the Company as defined in the warrant agreement) within our control, the holder
of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment of the warrants, cash consideration
equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction is not within our control, the
warrant holder would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, in the event of
a change in control of the Company or a sale or transfer of all or substantially all of our assets, as defined in the 2023 Warrants,
to the extent that the warrants issued to the institutional investor are outstanding at the effective date that such a transaction is
closed, this &ldquo;fundamental transaction&rdquo; provision would entitle the holder to substantial cash consideration, thus reducing
the amounts to be retained by us or potentially distributable to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>February 2025 Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 11, 2025, we entered
into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with two institutional investors (the &ldquo;Selling Stockholders&rdquo;).
Pursuant to the Purchase Agreement, on February 13, 2025, we sold 434,784 shares of common stock at a price of $2.415 per share and raised
gross proceeds of approximately $1,050,000. As part of this financing, we sold warrants to the institutional investors to purchase 434,784
shares of common stock (the &ldquo;2025 Warrants&rdquo;). Such Warrants had an initial exercise price of $2.29 per share, were immediately
exercisable upon issuance, and expire five years thereafter on February 13, 2030. We also issued warrants to the placement agent to purchase
32,609 shares of common stock at an exercise price of $3.0188 per share and expiring on February 13, 2030 (the &ldquo;2025 Placement
Agent Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The exercise prices of the warrants
issued to the institutional investors and to the placement agent are subject to customary adjustments for stock splits, stock dividends,
stock combinations, reclassifications, reorganizations, or similar events affecting our common stock. In addition, the warrants issued
to the institutional investors contain a &ldquo;fundamental transaction&rdquo; provision whereby in the event of a fundamental transaction
(including a sale or transfer of assets or ownership of the Company as defined in the warrant agreement) within our control, the holders
of the unexercised common stock warrants would be entitled to receive, in exchange for extinguishment of the warrants, cash consideration
equal to a Black-Scholes valuation, as defined in the warrant agreement. If such fundamental transaction is not within our control, the
warrant holders would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, in the event of
a change in control of the Company or a sale or transfer of all or substantially all of our assets, as defined in the 2025 Warrants,
to the extent that the warrants issued to the institutional investors are outstanding at the effective date that such a transaction is
closed, this &ldquo;fundamental transaction&rdquo; provision would entitle the holders to substantial cash consideration, thus reducing
the amounts to be retained by us or potentially distributable to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement,
we agreed to file a registration statement on Form S-1 for the resale by the selling stockholders of the shares of common stock issuable
upon exercise of the 2025 Warrants and the 2025 Placement Agent Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are filing the registration
statement of which this prospectus forms a part to satisfy our obligations under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_003"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-size: 10pt"><I>Issuer:</I></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 68%; text-align: justify"><FONT STYLE="font-size: 10pt">Lixte Biotechnology Holdings, Inc. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt"><I>Number of shares of common stock being offered by Selling Stockholders:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 467,393 shares of common stock.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt"><I>Number of shares of common stock outstanding immediately prior to
    this offering:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">2,684,074 shares of common stock. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt"><I>Number of shares of common stock to be outstanding immediately after
    this offering:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 3,151,467 shares <SUP>(1) </SUP></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"><I>Use of proceeds:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We will not receive any of the proceeds from the
    sale of shares of our common stock being offered for sale by the Selling Stockholders. However, upon any cash exercise of the 2025
    Warrants and the 2025 Placement Agent Warrants, we will receive gross proceeds of up to $1,094,095.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"><I>Nasdaq trading symbol:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our common stock currently trades on Nasdaq under
    the symbol &ldquo;LIXT&rdquo;. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt"><I>Transfer agent and registrar:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The transfer agent and registrar for our common
    stock is Computershare Trust Company, N.A.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"><I>Risk factors:</I></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The securities offered by this prospectus are speculative and involve
    a high degree of risk. Investors purchasing securities should not purchase the securities unless they can afford the loss of their
    entire investment. See &ldquo;Risk Factors&rdquo; beginning on page 13.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after this offering, the Company will have
    3,151,467 shares of common stock outstanding assuming exercise of the 2025 Warrants and the 2025 Placement Agent Warrants as set
    forth above and will exclude:</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: .25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">72,917 shares of our common stock issuable upon
    the conversion of 350,000 shares of Series A Convertible Preferred Stock outstanding at a conversion rate of 0.2083 common shares
    per preferred share, reflecting a conversion price of $48.00 per common share;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">662,078 shares of common stock issuable upon the
    exercise of common stock options issued to members of management, consultants, and directors at a weighted average exercise price
    of $11.526 per share; </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">808,365 shares of common stock issuable upon exercise
    of outstanding common stock warrants at an average exercise price of $16.4074 per common share, including 137,700 shares of common
    stock issuable upon exercise of 137,700 publicly traded warrants at $57.00 per common share through November 30, 2025; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">133,339 shares of common stock reserved for future
    grants pursuant to our 2020 Stock Incentive Plan, as amended (the &ldquo;2020 Plan&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Investing in our common stock
is highly speculative and involves a significant degree of risk. You should carefully consider the following risks and uncertainties
as well as the risks and uncertainties described in the section entitled &ldquo;Risk Factors&rdquo; contained in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission, which filings are incorporated
in this prospectus by reference in their entirety, as well as in any prospectus supplement hereto. These risk factors could materially
and adversely affect our business, results of operations or financial condition. Our business faces significant risks and the risks described
below or incorporated by reference herein may not be the only risks we face. Additional risks not presently known to us or that we currently
believe are immaterial may materially affect our business, results of operations, or financial condition. If any of these risks occur,
the trading price of our common stock could decline and you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to the Development and Regulatory
Approval of Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A clinical trial hold due to serious adverse
events could delay or halt the development of our product candidate. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Our lead drug candidate, LB-100,
is currently undergoing various clinical trials, and there is a risk that one or more of these trials could be placed on hold by regulatory
authorities due to serious adverse events (SAEs) related to our drug candidate or to another company&rsquo;s drug used in combination
in one of our clinical trials. It is possible that the SAEs could be attributable to our drug candidate and could include, but not be
limited to, unexpected severe side effects, treatment-related deaths, or long-term health complications. A dose given could result in
non-tolerable adverse events defined as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered
too high and unsafe. Further treatment is only allowed at lower dose-levels that have previously been found safe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">If an SAE or a pattern of SAEs
is observed during the course of a clinical trial involving our drug candidate, the U.S. Food and Drug Administration (FDA), European
Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring us to pause or discontinue further enrollment
and dosing in our clinical trial. It is also possible that the clinical trial could be terminated. Any of these actions could delay or
halt the development of our drug candidate, increase development costs, and negatively impact our ability to ultimately achieve regulatory
approval. Additionally, if an SAE is confirmed to be drug-related, we may be required to conduct additional studies, modify the study
design, or abandon further development of the drug candidate altogether, which could materially impact our business, financial condition,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The occurrence of an SAE and
any resulting clinical hold could also harm our reputation with patients, physicians, health institutions, and investors, diminish our
ability to attract clinical trial participants, and damage our ability to interest investors and obtain financing in the future. There
can be no assurance that we will not experience such SAEs in the future or that any related clinical hold will be lifted in a timely
manner, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The principal investigator
of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating two SAEs observed
in the clinical trial that was launched in August 2024. The Institutional Review Board (the &ldquo;IRB&rdquo;) of the Netherlands Cancer
Institute (&ldquo;NKI&rdquo;) has put the colorectal cancer study on hold. The adverse reactions that developed in the two patients were
dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and atezolizumab in one
patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second patient. The patient
who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea. The patient with fever
and aphasia fully recovered from the adverse events with supportive medication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Given the identified adverse
events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study at the NKI information
as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information about the mode
of action of the combination of LB-100 and atezolizumab. The principal investigator is preparing a response to the IRB detailing the
safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The reported adverse events
in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or in combination with other
cancer drugs. Through February 2025, a total of 78 patient have received or are receiving experimental treatment with LB-100. It is expected
that it will take at least two months to prepare a detailed response to the IRB, during which time the Company intends to update the
safety overview of LB-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to this Offering and Ownership of
our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have a history of losses, expect to continue
to incur losses in the near term and may not achieve or sustain profitability in the future, and as a result, our management has identified,
and our auditors agreed that there is a substantial doubt about our ability to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We have incurred significant
losses since our inception. We experienced net losses of $3,585,965 and $5,087,029 for the years ended December 31, 2024 and 2023, respectively.
We expect our operating losses will continue, or even increase, at least through the near term. You should not rely upon our past results
as indicative of future performance. We will not reach profitability in the near future or at any specific time in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The report of our independent
registered public accounting firm that accompanies our audited consolidated financial statements in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as
a going concern. Our consolidated financial statements do not include any adjustments that might result if we are unable to continue
as a going concern. If we are unable to continue as a going concern, holders of our securities might lose their entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are currently not in compliance with the
Nasdaq continued listing requirements. If we are unable to regain compliance with Nasdaq&rsquo;s listing requirements, our securities
could be delisted, which could affect our common stock&rsquo;s market price and liquidity and reduce our ability to raise capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, we announced
via Current Report on Form 8-K that we received a letter from the Listing Qualifications Department (the &ldquo;Staff&rdquo;) of the
Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) on August 19, 2024 indicating that we were not in compliance with the minimum stockholders&rsquo;
equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the &ldquo;Stockholders&rsquo;
Equity Requirement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 3, 2024, we submitted
a plan to the Staff to regain compliance with the Stockholders&rsquo; Equity Requirement, which outlined our proposed initiatives to
regain compliance by raising equity capital through various registered equity offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 21, 2024, the Staff
provided notice (the &ldquo;Notice&rdquo;) to us that it had granted an extension through February 18, 2025 to regain compliance with
the Stockholders&rsquo; Equity Requirement, which required that we complete our capital raising initiatives and evidence compliance with
the Stockholders&rsquo; Equity Requirement through filing a Current Report on Form 8-K with the Securities and Exchange Commission providing
certain required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of February 18, 2025, we
had not regained compliance with the Stockholders&rsquo; Equity Requirement. Accordingly, on February 19, 2025, we received a Staff determination
letter from the Staff stating that we did not meet the terms of the extension because we did not complete our proposed financing initiatives
to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We timely requested a Hearing
before a Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;), which automatically stayed Nasdaq&rsquo;s suspension or delisting of our common
shares and warrants pending the Panel&rsquo;s decision. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant us
an additional extension through no later than August 18, 2025. However, there can be no assurances that the Hearings Panel will grant
us an extension of time to regain compliance, or that we will be able to regain compliance during an extension period. During the hearings
process our common shares and warrants will continue to trade on The Nasdaq Capital Market.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to take reasonable
measures available to regain compliance under Nasdaq&rsquo;s listing rules and to remain listed on Nasdaq. However, there can be no assurances
that we will ultimately regain compliance with the Stockholders&rsquo; Equity Rule, or be able to maintain compliance with all other
applicable requirements for continued listing on Nasdaq. Our failure to meet these requirements may result in our securities being delisted
from Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot assure you that we
will be able to regain compliance with Nasdaq listing standards. Our failure to continue to meet these requirements would result in our
common stock being delisted from Nasdaq, and if our common stock is delisted, the warrants issued in our public offering would also be
delisted. We and holders of our securities could be materially adversely impacted if our securities are delisted from Nasdaq. In particular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: .5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">we may be unable to raise equity capital on acceptable
    terms or at all;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">we may lose the confidence of our clinical partners,
    which would jeopardize our ability to continue our clinical trials as currently conducted;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the price of our common stock will likely decrease
    as a result of the loss of market efficiencies associated with Nasdaq and the loss of federal pre-emption of state securities laws;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">holders may be unable to sell or purchase our
    securities when they wish to do so;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">we may become subject to stockholder litigation;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">we may be unable to attract, or we may lose the
    interest of, institutional investors in our common stock;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">we may lose media and analyst coverage;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">our common stock could be considered a &ldquo;penny
    stock&rdquo;, which would likely limit the level of trading activity in the secondary market for our common stock; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">we would likely lose any active trading market
    for our common stock, as it may only be traded on one of the over-the-counter markets, if at all.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will have to seek to raise additional funds
to fund our operations, including the various clinical trials being currently conducted or will be conducted in the future. Depending
on the terms available to us, if these fund raising activities result in significant dilution, they may negatively impact the trading
price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any additional financing that
we secure may require the granting of rights, preferences or privileges senior to, or <I>pari passu </I>with, those of our common stock.
Any issuances by us of equity securities may be at or below the prevailing market price of our common stock and in any event may have
a dilutive impact on your ownership interest, which could cause the market price of our common stock to decline. We may also raise additional
funds through the incurrence of debt or the issuance or sale of other securities or instruments senior to our shares of common stock,
which may be highly dilutive. The holders of any securities or instruments we may issue may have rights superior to the rights of our
common stockholders. If we experience dilution from the issuance of additional securities and we grant superior rights to new securities
over holders of our common stock, it may negatively impact the trading price of our common stock and you may lose all or part of your
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As part of the Company&rsquo;s ongoing process
of evaluating various alternatives to obtain the capital required to fund its operations and maintain its listing on Nasdaq, management
may decide to consider a wide variety of strategic alternatives, and there can be no assurances that any such transaction, if implemented,
would enhance stockholder value, and could be highly dilutive to existing stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is evaluating various
alternatives to obtain the capital required to fund its operations and maintain its listing on Nasdaq, including merger or acquisition
opportunities (including reverse mergers) and funding transactions involving a change in control. There can be no assurances that the
evaluation process will result in the identification of an appropriate transaction, the negotiation and execution of a definitive agreement
to effect such a transaction, or that any such transaction will ultimately be approved by the Company&rsquo;s stockholders and then be
consummated. Depending on various factors, many of which are outside the control of the Company, our failure to enter into and consummate
a strategic transaction could have a material adverse effect on our ability to continue to operate and finance our business, and on the
market price of our common stock. Even if such a strategic transaction is consummated, there can be no assurances that it will enhance
stockholder value, and it may result in substantial dilution to existing stockholders. Any potential transaction would be dependent on
a number of factors that may be outside of our control, including, among other things, market conditions, industry trends, the interest
of third parties in a potential transaction with the Company, and the availability of appropriate financing for such a transaction. If
we are unable to raise the required capital to fund our operations, or to enter into a strategic transaction in the near future, we may
not be able to maintain our listing on Nasdaq, and we may need to curtail or cease operations, which could result in a total loss of
stockholders&rsquo; investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The price of our common stock or warrants might
fluctuate substantially.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should consider an investment
in our common stock and warrants to be risky. Some factors that might cause the market price of our common stock or warrants to fluctuate,
in addition to the other risks mentioned in this &ldquo;Risk Factors&rdquo;, are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sale of our common stock by our stockholders, executives, and directors
    and our stockholders;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">volatility and limitations in trading volumes of our shares of common
    stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain financings to conduct and complete research and
    development activities including, but not limited to, our clinical trials, and other business activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the timing and success of introductions of new products by us or our
    competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers
    or strategic partners;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">network outages or security breaches;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to secure resources and the necessary personnel to conduct
    clinical trials on our desired schedule;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">commencement, enrollment or results of our clinical trials for our
    lead product candidate or any future clinical trials we might conduct;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in the development status of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delays or adverse developments or perceived adverse developments
    with respect to the FDA&rsquo;s review of our planned preclinical and clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay in our submission for studies or product approvals or adverse
    regulatory decisions, including failure to receive regulatory approval for our lead product candidate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unanticipated safety concerns related to the use of our lead product
    candidate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failures to meet external expectations or management guidance;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in our capital structure or dividend policy, future issuances
    of securities, sales of large blocks of common stock by our stockholders;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our cash position;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements and events surrounding financing efforts, including debt
    and equity securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our inability to enter into new markets or develop new products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reputational issues;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competition from existing technologies and products or new technologies
    and products that might emerge;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements of acquisitions, partnerships, collaborations, joint
    ventures, new products, capital commitments, or other events by us or our competitors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in general economic, political and market conditions in or
    any of the regions in which we conduct our business;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in industry conditions or perceptions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in valuations of similar companies or groups of companies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">analyst research reports, recommendation and changes in recommendations,
    price targets, and withdrawals of coverage;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">departures and additions of key personnel;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disputes and litigations related to intellectual properties, proprietary
    rights, and contractual obligations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in applicable laws, rules, regulations, or accounting practices
    and other dynamics; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other events or factors, many of which might be out of our control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, if the market for
stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence,
the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations.
If any of the foregoing occurs, it could cause our stock price to fall and might expose us to lawsuits that, even if unsuccessful, could
be costly to defend and a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><B><I>Provisions of the Warrants issued
in the 2023 Financing and 2025 Financing could discourage an acquisition of us by a third party.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain provisions of the 2023
Warrants and 2025 Warrants could make it more difficult or expensive for a third party to acquire us. Such Warrants prohibit us from
engaging in certain transactions constituting &ldquo;fundamental transactions&rdquo; unless, among other things, the surviving entity
assumes our obligations under such Warrants. These and other provisions of the Common Warrants offered by this prospectus could prevent
or deter a third party from acquiring us even where the acquisition could be beneficial to you. Also, we may be required to redeem these
Warrants for a cash payment calculated pursuant to the Black-Scholes option-pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>An active, liquid and orderly trading market
for our common stock may not develop, the price of our stock may be volatile, and you could lose all or part of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Even though our common stock
is currently listed on Nasdaq, we cannot predict the extent to which investor interest in our Company will lead to the development of
an active trading market in our securities or how liquid that market might become. If such a market does not develop or is not sustained,
it may be difficult for you to sell your shares of common stock at the time you wish to sell them, at a price that is attractive to you,
or at all. There could be extreme fluctuations in the price of our common stock if there are a limited number of shares in our public
float.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The trading price of our common
stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control.
Our stock price could be subject to wide fluctuations in response to a variety of factors, which include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .5in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether we achieve our anticipated corporate objectives;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">actual or anticipated fluctuations in our quarterly
    or annual operating results;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in our financial or operational estimates;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to implement our operational plans;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in the economic performance or market
    valuations of companies similar to ours; and</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">general economic or political conditions in the
    United States or elsewhere.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In addition, broad market and
industry factors may seriously affect the market price of companies&rsquo; stock, including ours, regardless of actual operating performance.
In the past, following periods of volatility in the overall market and the market price of a particular company&rsquo;s securities, securities
class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in
substantial costs and a diversion of our management&rsquo;s attention and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our outstanding Warrants may cause the trading
price of our common stock to decrease.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Depending on the price of our
common stock, the number of shares of common stock issuable pursuant to the exercise of the Warrants issued in the 2023 Financing and
2025 Financing, could result in an immediate decrease in the trading price of our common stock. If the bid price of our common stock
falls below $1.00 per share for 30 consecutive business days, we would no longer meet Nasdaq&rsquo;s minimum bid price requirement and
our common stock would be subject to delisting. We cannot predict the effect, if any, that the availability of shares for future sale
represented by such Warrants will have on the trading price of our common stock from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If our shares of common stock become subject
to the penny stock rules, it would become more difficult to trade our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Securities and Exchange
Commission has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are
generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges
or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to
transactions in such securities is provided by the exchange or system. If we do not retain a listing on Nasdaq and if the price of our
common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before
a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified
information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from
those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser
and receive (i) the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement
to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements
may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have
difficulty selling their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we were to dissolve, the holders of our
securities may lose all or substantial amounts of their investments.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">If we were to dissolve as a
corporation, as part of ceasing to do business or otherwise, we will be required to pay all amounts owed to any creditors before distributing
any assets to holders of our capital stock. There is a risk that in the event of such a dissolution, there will be insufficient funds
to repay amounts owed to holders of any of our indebtedness and insufficient assets to distribute to our capital stockholders, in which
case investors could lose their entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If securities or industry analysts do not publish
or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our securities
adversely, our stock price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The trading market for our
common stock is influenced by the research and reports that industry or securities analysts may publish about us, our business, our market
or our competitors. If any of the analysts who may cover us change their recommendation regarding our common stock adversely, or provide
more favorable relative recommendations about our competitors, our stock price would likely decline. If any of the analysts who may cover
us were to cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets,
which in turn could cause our stock price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>In making your investment decision, you should
understand that neither we nor the Selling Stockholders have authorized any other party to provide you with information concerning us
or this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">You should carefully evaluate
all of the information in this prospectus before investing in our company. We may receive media coverage regarding our company, including
coverage that is not directly attributable to statements made by our officers, that incorrectly reports on statements made by our officers
or employees, or that is misleading as a result of omitting information provided by us, our officers or employees. We and the placement
agent have not authorized any other party to provide you with information concerning us or this offering, and you should not rely on
unauthorized information in making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_005"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus, and the documents
incorporated by reference herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). All statements other than statements of historical facts contained in this prospectus, including statements regarding our
future results of operations and financial position, business strategy and plans and our objectives for future operations, are forward-looking
statements. The words &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;could&rdquo;, &ldquo;estimate&rdquo;, &ldquo;expect&rdquo;,
&ldquo;forecast&rdquo;, &ldquo;intend&rdquo;, &ldquo;may&rdquo;, &ldquo;plan&rdquo;, &ldquo;potential&rdquo;, &ldquo;should&rdquo;, &ldquo;will&rdquo;,
&ldquo;would&rdquo;, &ldquo;might&rdquo;, and similar expressions are intended to identify forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results
or anticipated results, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We are engaged in early-stage research and as
    such might not be successful in our efforts to develop a portfolio of commercially viable products;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We have incurred substantial losses since our
    inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our independent registered public accounting firm
    has expressed substantial doubt about our ability to continue as a going concern;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We need significant additional financing to fund
    our operations and complete the development and, if approved, the commercialization of our lead product candidate, LB-100. If we
    are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization
    efforts;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We currently have no source of revenues. We might
    never generate revenues or achieve profitability;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to use net operating losses to offset
    future taxable income might be subject to limitations;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Clinical-stage biopharmaceutical companies with
    product candidates in clinical development face a wide range of challenging activities which might entail substantial risk;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might find it difficult to enroll patients
    in our clinical trials which could delay or prevent the start of clinical trials for our product candidate;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The results of preclinical studies or earlier
    clinical trials are not necessarily predictive of future results. Our lead product candidate in clinical trials, and any other product
    candidates that might advance into clinical trials, might not have favorable results in later clinical trials or receive regulatory
    approval;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Clinical drug development involves a lengthy and
    expensive process with an uncertain outcome;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">There is a risk that one or more of our clinical
    trials could be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to our drug candidate or to
    another company&rsquo;s drug used in combination in one of our clinical trials.&nbsp;&nbsp;It is possible that the SAEs could be
    attributable to our drug candidate and could include, but not be limited to, unexpected severe side effects, treatment-related deaths,
    or long-term health complications. A dose given could result in non-tolerable adverse events defined as dose-limiting toxicity (DLT).
    When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe.&nbsp;&nbsp;Further treatment is only
    allowed at lower dose-levels that have previously been found safe.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Risks associated with operating in foreign countries
    could materially adversely affect our product development;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our current and future product candidates, the
    methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay
    or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences
    following any regulatory approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our product development program might not uncover
    all possible adverse events that patients who take our lead product candidate may experience. The number of subjects exposed to our
    lead product candidate and the average exposure time in the clinical development program might be inadequate to detect rare adverse
    events or chance findings that might only be detected once the product is administered to more patients and for greater periods of
    time;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our future success is dependent on the regulatory
    approval of our lead product candidate;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our lead product candidate and future product
    candidates could fail to receive regulatory approval from the FDA;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Failure to obtain regulatory approval in international
    jurisdictions would prevent our lead product candidate from being marketed abroad;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Even if our current primary product candidate
    received regulatory approval, it might still face future development and regulatory difficulties;</FONT></TD></TR>
  <TR>
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We depend on certain key scientific personnel
    for our success who do not work full time for us. The loss of any such personnel could adversely affect our business, financial condition
    and results of operations;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We expect to rely heavily on third parties for
    the conduct of clinical trials of our product candidates. If these clinical trials are not successful, or if we or our collaborators
    are not able to obtain the necessary regulatory approvals, we will not be able to commercialize our product candidates;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Business interruptions could adversely affect
    future operations, revenues, and financial conditions, and might increase our costs and expenses;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our failure to find third party collaborators
    to assist or share in the costs of product development could materially harm our business, financial condition or results of operations;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might be subject to claims by third parties
    asserting that our employees, consultants, collaborators contractors or we have misappropriated their intellectual property, or claiming
    ownership of what we regard as our own intellectual property;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We cannot be certain we will be able to obtain
    patent protection to protect our product candidates and technology;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">If we do not obtain patent term extension in the
    United States under the Hatch-Waxman Act or in foreign countries under similar legislation, our business might be materially harmed;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">If we fail to comply with our obligations in agreements
    under which we have licensed or, might license, intellectual property rights from third parties, or if we otherwise experience disruptions
    to our business relationships with our licensors, we could lose rights that are important to our business;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might infringe the intellectual property rights
    of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing
    our product candidates;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might be subject to claims that our employees,
    consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of one or more third parties;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our intellectual property might not be sufficient
    to protect our intended products from competition, which might negatively affect our business as well as limit our partnership or
    acquisition appeal;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">If we are not able to protect and control our
    unpatented trade secrets, know-how and other technological innovation, we might suffer competitive harm;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might incur substantial costs prosecuting our
    patent applications, maintaining our patents and patent applications, enforcing our patents, defending against third party patent
    infringement suits, seeking invalidation of third party patents or in-licensing third party intellectual property, as a result of
    litigation or other proceedings relating to patent and other intellectual property rights;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">If we are unable to protect our intellectual property
    rights, our competitors might develop and market products with similar or identical features that might reduce demand for our potential
    products;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our commercial success depends upon attaining
    significant market acceptance of our current product candidate and future product candidates, if approved, among physicians, patients,
    healthcare payors and cancer treatment centers;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Even if we are able to commercialize our lead
    product candidate or any future product candidates, the products might not receive coverage or adequate reimbursement from third
    party payors in the United States and in other countries in which we seek to commercialize our intended products, which could harm
    our business;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Healthcare legislative measures aimed at reducing
    healthcare costs might have a material adverse effect on our business and results of operations;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Price controls might be imposed in foreign markets,
    which might adversely affect our future profitability;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our relationships with customers and third party
    payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose
    us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. If
    we or they are unable to comply with these provisions, we might become subject to civil and criminal investigations and proceedings
    that could have a material adverse effect on our business, financial condition and prospects;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our employees might engage in misconduct or other
    improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability
    for us and harm our reputation;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Product liability lawsuits against us could cause
    us to incur substantial liabilities and to limit commercialization of any products that we might develop;</FONT></TD></TR>
  <TR>
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We face substantial competition, which might result
    in others discovering, developing or commercializing products before or more successfully than we do;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Significant disruptions of information technology
    systems, computer system failures or breaches of information and cyber security could adversely affect our business;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might need to grow the size of our organization
    in the future, and we might experience difficulties in managing this growth;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Inadequate funding for the FDA, the SEC and other
    government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services
    from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions
    on which the operation of our business might rely, which could negatively impact our business;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Unstable market and economic conditions and adverse
    developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business,
    financial condition and stock price;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We are a &ldquo;smaller reporting company&rdquo;
    and we have elected to comply with certain reduced reporting and disclosure requirements which could make its common stock less attractive
    to investors;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The price of our common stock might fluctuate
    substantially;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">A sale or perceived sale of a substantial number
    of shares of our common stock might cause the price of our common stock to decline;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Market and economic conditions might negatively
    impact our business, financial condition and share price;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">If securities or industry analysts do not publish
    research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume might decline;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Future sales and issuances of our common stock
    could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We do not intend to pay cash dividends on our
    shares of common stock so any returns will be limited to the value of our shares;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">We might be at risk of securities class action
    litigation;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our Certificate of Incorporation and our Amended
    and Restated Bylaws, and Delaware law might have anti-takeover effects that could discourage, delay or prevent a change in control,
    which might cause our stock price to decline;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Financial reporting obligations of being a public
    company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to
    compliance matters; and</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">If we fail to comply with the rules under Sarbanes-Oxley
    related to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our
    internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We caution you that the foregoing
list may not contain all of the forward-looking statements made in this prospectus. We have based these forward-looking statements largely
on our current expectations about future events and financial trends that we believe may affect our financial condition, results of operations,
business strategy, short term and long-term business operations and objectives, and financial needs. These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;Risk Factors&rdquo;. Moreover, we
operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management
to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and
actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should not rely upon forward-looking
statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for
any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should read this prospectus
and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the
registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity,
performance and events and circumstances may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will not receive any of the
proceeds from any sale or other disposition of the common stock covered by this prospectus. All proceeds from the sale of the common
stock will be paid directly to the selling stockholders. However, we will receive proceeds upon the cash exercise of the 2025 Warrants
and the 2025 Placement Agent Warrants. Assuming full cash exercise of the 2025 Warrants and the 2025 Placement Agent Warrants, we would
receive approximately $1,094,095. We currently intend to use any cash proceeds from a Warrant exercise for working capital and continuing
operating expenses, including, without limitation, for further clinical development of our lead compound LB-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_007"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The following table sets forth
our capitalization as of December 31, 2024 as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">on an actual basis; and</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">on an as adjusted basis, to reflect (i) the
    issuance of 434,784 common shares included in the sale of 434,784 units on February 11, 2025, (ii) the issuance of 434,784 common
    shares issuable upon exercise of the warrants included in the sale of 434,784 units on February 11, 2025, at an exercise price of
    $2.29 per share; and (iii) the issuance of 32,609 common shares issuable upon exercise of the warrants issued to the placement agent
    in the sale of 434,784 units on February 11, 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 64%; padding-bottom: 1pt">Cash</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 1pt solid; text-align: right">1,038,952</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 1pt solid; text-align: right">2,928,800</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, issued and outstanding
    350,000 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock, $0.0001 par value per share; 100,000,000 shares authorized, 2,249,290 issued and outstanding
    shares actual, and 3,151,467 shares, on an as adjusted basis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,394,687</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,284,445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52,067,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52,068,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">827,219</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717,067</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">827,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,717,067</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of March 31, 2025, the Company
will have 3,151,467 shares of common stock outstanding assuming exercise of the 434,784 warrants and the 32,609 warrants as set forth
in the table above and will exclude:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: .25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">72,917 shares of our common stock issuable upon
    the conversion of 350,000 shares of Series A Convertible Preferred Stock outstanding at a conversion rate of 0.2083 common shares
    per preferred share, reflecting a conversion price of $48.00 per common share;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">662,078 shares of common stock issuable upon the
    exercise of common stock options issued to members of management, consultants, and directors at a weighted average exercise price
    of $11.526 per share; </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">808,365 shares of common stock issuable upon exercise
    of outstanding common stock warrants at an average exercise price of $16.4074 per common share, including 137,700 shares of common
    stock issuable upon exercise of 137,700 publicly traded warrants at $57.00 per common share through November 30, 2025; and</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">133,339 shares of common stock reserved for future
    grants pursuant to our 2020 Stock Incentive Plan, as amended (the &ldquo;2020 Plan&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_008"></A>SELECTED HISTORICAL FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Consolidated Statements of Operations Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Costs and expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Research and development costs</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">726,232</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">898,100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">General and administrative costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,846,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,192,136</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,572,789</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,090,236</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,572,789</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,090,236</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,486</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,821</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,233</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency gain (loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,403</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,954</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,585,965</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,087,029</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.59</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.66</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,249,290</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,915,838</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 1.5pt"><B>Consolidated Balance Sheet
Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 2.5pt">Total current assets</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">1,145,503</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">4,308,620</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,145,503</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,308,620</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">318,824</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">313,858</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">318,824</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">313,858</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred Stock, $0.0001 par value; authorized &ndash; 10,000,000 shares; issued and outstanding &ndash;
    350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion
    into common shares &ndash; 72,917 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock, $0.0001 par value; authorized &ndash; 100,000,000 shares; issued and outstanding &ndash;
    2,249,290 shares at December 31, 2024 and 2023, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,394,687</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,976,265</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52,067,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(48,481,728</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">827,219</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,994,762</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation,
as amended, authorizes the issuance of up to 100,000,000 shares of common stock, par value $0.0001 per share, and up to 10,000,000 shares
of preferred stock, par value $0.0001 per share. As of March 31, 2025, there were 2,684,074 shares of common stock outstanding, which
were held by 46 stockholders of record, and 350,000 shares of Series A Convertible Preferred Stock outstanding convertible into 72,917
shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 2, 2023, we effected
a reverse stock split of our common stock at a ratio of 1-for-10. All share and per share information presented in this prospectus reflects
the effect of the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each holder of common stock is
entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders, including the election
of directors. Our certificate of incorporation, as amended and bylaws do not provide for cumulative voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to preferences that may
be applicable to any then outstanding preferred stock, the holders of our outstanding shares of common stock are entitled to receive
dividends, if any, as may be declared from time to time by our Board of Directors out of legally available funds. In the event of our
liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available
for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation
preference granted to the holders of any outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Holders of our common stock have
no pre-emptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to the common stock.
The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of
the holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board of Directors is authorized,
without vote or action by our stockholders, to issue from time to time up to an aggregate of 10,000,000 shares of preferred stock in
one or more series and to fix or alter the designations, preferences, rights and any qualifications, limitations or restrictions of the
shares of each of these series, including, if applicable, the dividend rights and preferences, conversion rights, voting rights, terms
and rights of redemption, including without limitation sinking fund provisions, redemption price or prices, liquidation rights and preferences,
and the number of shares constituting any series. The issuance of preferred stock may have the effect of delaying, deferring or preventing
a change in control of us without further action by our stockholders and may adversely affect the dividend, liquidation and voting and
other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the
voting power of the holders of common stock, including the loss of voting control to others. We currently have no plans to issue any
additional shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that the ability to
issue preferred stock without the expense and delay of a special stockholders&rsquo; meeting provides us with increased flexibility in
structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. This also permits the
Board of Directors of the Company to issue preferred stock containing terms which could impede the completion of a takeover attempt.
This could discourage an acquisition attempt or other transaction which stockholders might believe to be in their best interests or in
which they might receive a premium for their stock over the then market price of the stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the 2023 Financing
and 2025 Financing, we issued warrants to purchase a total of 1,085,727 shares to the investors and placement agents, including Warrants
to purchase 583,334 shares of common stock exercisable at $6.00 per share to the investor in the 2023 Financing and Warrants to purchase
434,784 shares of common stock exercisable at $2.29 per share to the investors in the 2025 Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The exercise prices of the Warrants
are subject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar
events affecting our common stock. In addition, the Warrants contain a &ldquo;fundamental transaction&rdquo; provision which provides
that if any defined fundamental transactions are within our control and are consummated, the holder of the unexercised common stock Warrants
would be entitled to receive, at its option, in exchange for extinguishment of such Warrants, cash consideration equal to a Black-Scholes
valuation amount, as defined in the Warrant agreement. The fundamental transaction provision includes (i) a sale, lease, assignment,
transfer, conveyance or other disposition of all or substantially all of assets in one or a series of related transactions, or (ii) a
change in control of the Company by which it, directly or indirectly, in one or more related transactions, consummates a stock or share
purchase agreement or other business combination with another person or group, whereby such other person or group acquires more than
50% of the voting power of our common equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If such fundamental transaction
is not within our control, including not being approved by our Board of Directors, the Warrant holder would only be entitled to receive
the same type or form of consideration (and in the same proportion) equal to the Black-Scholes valuation amount of the remaining unexercised
portion of the Warrant on the date of consummation of such fundamental transaction as the holders of our common stock receive. Accordingly,
these Warrants are classified as a component of permanent stockholders&rsquo; equity. We will account for any cash payment for a Warrant
redemption as a distribution from stockholders&rsquo; equity, as and when a fundamental transaction is consummated and such cash payment
is required to be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Anti-Takeover Effects of Certain Provisions in
our Certificate and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: left"><B><I>Exclusive Forum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">The certificate of
incorporation provides that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware
shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a
claim of breach of fiduciary duty owed by any of our directors, officers, or other employee to us or to our stockholders, (iii) any action
asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, the certificate of incorporation
or the bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. However, this provision does not apply
to suits brought to enforce a duty or liability created by the Exchange Act. In addition, the Court of Chancery of the State of Delaware
and the federal district courts will have concurrent jurisdiction for the resolution of any suit brought to enforce any duty or liability
created by the Securities Act. Notwithstanding the foregoing, the inclusion of such provisions in the certificate of incorporation will
not be deemed to be a waiver by us or our stockholders of the obligation to comply with federal securities laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">Although we believe
these provisions benefit the Company by providing increased consistency in the application of Delaware law in the types of lawsuits to
which it applies, these provisions may have the effect of discouraging lawsuits against the Company&rsquo;s directors and officers. Furthermore,
the enforceability of choice of forum provisions in other companies&rsquo; certificates of incorporation has been challenged in legal
proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><B><I>Advance Notice of Stockholder Proposals
and Nominations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 0.5in">Our bylaws include
an advance notice procedure for stockholders to nominate candidates for election as directors or to bring other business before any meeting
of our stockholders. The stockholder notice procedure provides that only persons who are nominated by, or at the direction of, the Board
of Directors, or by a stockholder who has given timely written notice prior to the meeting at which directors are to be elected, will
be eligible for election as directors and that, at a stockholders&rsquo; meeting, only such business may be conducted as has been brought
before the meeting by, or at the direction of, the Board of Directors or by a stockholder who has given timely written notice of such
stockholder&rsquo;s intention to bring such business before such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 0.5in">Under the stockholder
notice procedure, for notice of stockholder nominations or other business to be made at a stockholders&rsquo; meeting to be timely, such
notice must be received by us not earlier than the close of business on the 120th calendar day and not later than the close of business
on the 90th calendar day prior to the one-year anniversary of the immediately preceding year&rsquo;s annual meeting or as otherwise provided
in the bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify; text-indent: 0.5in">A stockholder&rsquo;s
notice to us proposing to nominate a person for election as a director or proposing other business must contain certain information specified
in the bylaws, including the identity and address of the nominating stockholder, a representation that the stockholder is a record holder
of our stock entitled to vote at the meeting and information regarding each proposed nominee or each proposed matter of business that
would be required under the federal securities laws to be included in a proxy statement soliciting proxies for the proposed nominee or
the proposed matter of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">The stockholder notice
procedure may have the effect of precluding a contest for the election of directors or the consideration of stockholder proposals if
the proper procedures are not followed, and of discouraging or deterring a third party from conducting a solicitation of proxies to elect
its own slate of directors or to approve its own proposal, without regard to whether consideration of such nominees or proposals might
be harmful or beneficial to us and our stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: left"><B><I>Restrictions on Call of Special
Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">Our bylaws provide
that special meetings of stockholders can only be called by the Board of Directors, Chief Executive Officer or President (in the absence
of a Chief Executive Officer), but not by our stockholders or any other person or persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: left"><B><I>No Cumulative Voting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The certificate of incorporation
does not authorize cumulative voting for the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: left"><B><I>Preferred Stock Authorization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board of Directors, without
stockholder approval, has the authority under our certificate of incorporation to issue preferred stock with rights superior to the rights
of the holders of common stock. As a result, preferred stock, while not intended as a defensive measure against takeovers, could be issued
quickly and easily, could adversely affect the rights of holders of common stock and could be issued with terms calculated to delay or
prevent a change of control of the Company or make removal of management more difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The common stock being offered
by the selling stockholders are those issuable to the selling stockholder upon exercise of the 2025 Warrants and the 2025 Placement Agent
Warrants. For additional information regarding the issuance of the 2025 Warrants and the 2025 Placement Agent Warrants, see &ldquo;2025
Financing&rdquo; above. We are registering the shares of common stock in order to permit the selling stockholders to offer the shares
for resale from time to time. Except for the beneficial ownership of securities of the Company, including the 2025 Warrants and the 2025
Placement Agent Warrants, neither the selling stockholders nor any persons who have control over the selling stockholders has had any
material relationship with us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The table below lists the selling
stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the
shares of Common Stock by the selling stockholders. The second column lists the number of shares of Common Stock beneficially owned by
the selling stockholders, based on their ownership of the shares of Common Stock, options to purchase Common Stock, and warrants to purchase
Common Stock, as of March 31, 2025, assuming exercise in full of the 2025 Warrants and the 2025 Placement Agent Warrants held by the
selling stockholders on that date, without regard to any limitations on exercises. The third column lists the maximum number of shares
of Common Stock that may be sold or otherwise disposed of by the selling stockholders pursuant to the registration statement of which
this prospectus forms a part. The selling stockholders may sell or otherwise dispose of some, all or none of its shares. The fourth column
assumes the sale of all of the shares of Common Stock offered by the selling stockholders pursuant to this prospectus, without regard
to any limitations on exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the terms of the 2025 Warrants,
the selling stockholders may not exercise the Warrants to the extent such exercise would cause the selling stockholders, together with
their affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as
applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination the shares of
common stock issuable upon exercise of the Warrants which have not been exercised. The number of shares of common stock owned prior to
the offering in the second column and the number of shares of common stock owned after the offering in the fourth column do not reflect
this limitation. The selling stockholders may sell all, some or none of their shares in this offering. See &ldquo;Plan of Distribution&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares Owned</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Immediately After Sale of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum Number of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares in this Offering</B></P></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of Selling Stockholder</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of Shares of Common Stock</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Owned Prior to</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>this Offering</B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum Number of Shares of Common Stock to
    be Sold</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to this</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Prospectus</B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Outstanding</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares of Common Stock<SUP>(3)</SUP></B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Intracoastal Capital LLC<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">219,495</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">217,392</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,103</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Gundyco ITF Orca Capital<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">217,392</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">217,392</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Michael Vasinkevich<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,910</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,910</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Noam Rubinstein<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,272</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,272</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Craig Schwabe<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,101</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,101</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Charles Worthman<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">326</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">326</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>469,496</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>467,393</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>2,103</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>*</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>%</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">*Less than 1.0%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents (i) 2,103 shares of common
                                            stock issuable upon exercise of our public warrants and (ii) 217,392 shares of common stock
                                            issuable upon exercise of Warrants. The securities are held by Intracoastal Capital LLC.,
                                            a Delaware limited liability company (&ldquo;Intracoastal&rdquo;). The Warrants are subject
                                            to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling
                                            stockholder from exercising that portion of the Warrants that would result in the Selling
                                            Stockholder and its affiliates owning, after exercise, a number of shares of common stock
                                            in excess of the beneficial ownership limitation. The address of Intracoastal is 245 Palm
                                            Trail, Delray Beach, Florida 33483.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents 217,392 shares of common
                                            stock issuable upon exercise of Warrants. The securities are held by Orca Capital AG, a German
                                            corporation. The Warrants are subject to a beneficial ownership limitation of 4.99%, which
                                            such limitation restricts the selling stockholder from exercising that portion of the Warrants
                                            that would result in the Selling Stockholder and its affiliates owning, after exercise, a
                                            number of shares of common stock in excess of the beneficial ownership limitation. The address
                                            of Orca Capital AG is Sperlring 2 85276, Hettenshausen, Germany.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Percentages are based on 3,151,467 shares
                                            of common stock assumed to be outstanding immediately after this offering.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Represents shares of common stock issuable
                                            upon exercise of the 2025 Placement Agent Warrants issued as compensation to H.C. Wainwright
                                            &amp; Co., LLC, as our exclusive placement agent, in conjunction with the February 2025 Financing.
                                            Each of the selling stockholders is affiliated with H.C. Wainwright &amp; Co., LLC, a registered
                                            broker dealer with a registered address of H.C. Wainwright &amp; Co., LLC, 430 Park Ave,
                                            3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the securities
                                            held. The selling stockholder acquired the 2025 Placement Agent Warrants in the ordinary
                                            course of business and, at the time the 2025 Placement Agent Warrants were acquired, the
                                            selling stockholder had no agreement or understanding, directly or indirectly, with any person
                                            to distribute such securities.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_010"></A>Plan of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any of their pledges, assignees and successors-in-interest may from time to time, sell any or all of their shares of common stock covered
hereby on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the common stock is traded or in
private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following
methods when selling shares of common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; block trades in which
the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate
the transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; an exchange distribution
in accordance with the rules of the applicable exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; privately negotiated
transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; settlement of short sales;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; in transactions through
broker-dealers that agree with the selling stockholder to sell a specified number of shares of common stock at a stipulated price per
share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; through the written settlement
of options or other hedging transactions, whether through an options exchange or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; a combination of any
such methods of sale; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; any other method permitted
pursuant to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
also sell shares of common stock under Rule 144 or any other exemption from registration under the Securities Act, if available, rather
than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by the
selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares of common stock, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with Rule 2121 of the Financial Industry Regulatory Authority, or FINRA; and
in the case of a principal transaction, a markup or markdown in compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the sale of
the shares of common stock covered by this prospectus or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course
of hedging the positions they assume. The selling stockholders may also sell shares of common stock short and deliver these shares to
close out their short positions, or loan or pledge the shares to broker-dealers that in turn may sell these shares. The selling stockholders
may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of shares of common stock covered by this
prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or
amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any broker-dealers or agents that are involved in selling the shares of common stock covered hereby may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under
the Securities Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are required to pay certain
fees and expenses incurred by us incident to the registration of the shares of common stock covered hereby. We have agreed to indemnify
the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We agreed to keep the registration
statement of which this prospectus forms a part effective until the selling stockholders do not own any 2025 Warrants or common stock
issuable upon exercise thereof. The shares of common stock will be sold only through registered or licensed brokers or dealers if required
under applicable state securities laws. In addition, in certain states, the shares of common stock covered hereby may not be sold unless
they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under applicable rules and regulations
under the Securities Exchange Act of 1934, or the Exchange Act, any person engaged in the distribution of the shares of common stock
covered hereby may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted
period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject
to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing
of purchases and sales of the common stock by the selling stockholder or any other person. We will make copies of this prospectus available
to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to
the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is currently
listed on the Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. The warrants issued in our November 2020 public offering are
currently listed on the Nasdaq Capital Market under the symbol &ldquo;LIXTW&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock and the warrants issued in our November 2020 public offering is Computershare Trust Company, N.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered by this prospectus will be passed upon by TroyGould PC, Los Angeles, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Weinberg &amp; Company, P.A.,
our independent, registered public accounting firm, has audited our consolidated financial statements as of December 31, 2024 and 2023
and for the years then ended included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is incorporated
by reference into this prospectus and elsewhere in the registration statement of which this prospectus is a part. Our financial statements
are incorporated by reference in reliance on Weinberg &amp; Company P.A.&rsquo;s report, which includes an explanatory paragraph regarding
substantial doubt about the Company&rsquo;s ability to continue as a going concern, given on their authority as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_013"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The SEC allows us to incorporate
by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring
you to those documents. The information incorporated by reference is considered to be part of this prospectus. Because we are incorporating
by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some
of the information included or incorporated in this prospectus. We incorporate by reference the documents listed below and all documents
subsequently filed with the SEC (excluding any portions of any Form 8-K that are not deemed &ldquo;filed&rdquo; pursuant to the General
Instructions of Form 8-K) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this prospectus and prior
to the date this offering is terminated or we issue all of the securities under this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: .5in">&nbsp;</TD>
    <TD STYLE="width: .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on </FONT><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225000208/form10-k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A></FONT> <FONT STYLE="font-size: 10pt">for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225001069/form8-k.htm" STYLE="-sec-extract: exhibit">January 6, 2025</A>,
    <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225006285/form8-k.htm" STYLE="-sec-extract: exhibit">February 13, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225007865/form8-k.htm" STYLE="-sec-extract: exhibit">February 21, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225008203/form8-k.htm" STYLE="-sec-extract: exhibit">February 25, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225009782/form8-k.htm" STYLE="-sec-extract: exhibit">March 11, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225009786/form8-k.htm" STYLE="-sec-extract: exhibit">March 11, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315225010282/form8-k.htm" STYLE="-sec-extract: exhibit">March 14, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000164117225000971/form8-k.htm" STYLE="-sec-extract: exhibit">March 27, 2025</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000164117225001763/form8-k.htm" STYLE="-sec-extract: exhibit">March 31, 2025</A>; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our common stock contained in the registration statement
    on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220021857/form8-a12b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form 8-A</FONT></A><FONT STYLE="font-size: 10pt">, filed with the SEC on November 17, 2020, and any amendment or report filed for the
    purpose of updating such description (including </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220004697/ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Exhibit 4.1</FONT></A> <FONT STYLE="font-size: 10pt">to the Annual Report on Form 10-K for the fiscal year ended December 31, 2023).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To obtain copies of these filings,
see &ldquo;Where You Can Find More Information&rdquo; in this prospectus. Nothing in this prospectus shall be deemed to incorporate information
furnished, but not filed, with the SEC, including pursuant to Item 2.02 or Item 7.01 of Form 8-K and any corresponding information or
exhibit furnished under Item 9.01 of Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information in this prospectus
supersedes related information in the documents listed above and information in subsequently filed documents supersedes related information
in both this prospectus and the incorporated documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_014"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to the periodic
reporting requirements of the Exchange Act, and we will file periodic reports, proxy statements and other information with the SEC. These
periodic reports, proxy statements and other information are available at www.sec.gov. We maintain a website at https://lixte.com. We
have not incorporated by reference into this prospectus the information contained in, or that can be accessed through, our website, and
you should not consider it to be a part of this prospectus. You may access our Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange
Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the SEC. You may also request a copy of these filings (other than exhibits to these documents unless the exhibits are specifically
incorporated by reference into these documents or referred to in this prospectus), at no cost, by writing us at 680 East Colorado Boulevard,
Suite 180, Pasadena, California 91101 or contacting us at (631) 830-7092.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC a
registration statement under the Securities Act relating to the offering of these securities. The registration statement, including the
attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the
information set forth in the registration statement. You may review a copy of the registration statement and the documents incorporated
by reference herein through the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="form424b4_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>LIXTE BIOTECHNOLOGY HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>467,393 Shares of Common Stock</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>434,784 Shares of Common Stock Issuable Upon
the Exercise of Outstanding 2025 Warrants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>32,609 Shares of Common Stock Issuable Upon
the Exercise of 2025 Placement Agent Warrants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">April 11, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b4_005.jpg
<TEXT>
begin 644 form424b4_005.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !X 1,# 2(  A$! Q$!_\0
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M:YN38X5=0SP!C Z'K7L_P:_;IO[2XL= ^*]@;N.X7RAXKTV(6<$) X%W:6C
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M_B1:'+IFN_M<>)](N1/:Z[XF'V;6O"7[/I86/V^T_P"$:-KI7B_X@_V>V?\
MA*F\/^$-6&F-X<\6::?XS?V4?V<?BS^V1\>_A1^S'\#?#MQX@^)WQ1\46WAS
MPWI]O#/]A@ANF^V:MXH\17=F"VC:#X-T&UU?Q!XLU_"#2_"^CWQ.?+PP!_NI
M45_"+_P7?_8$^$'_  39_P"#?GX.?LP_"BP1O^$;_:K^$&L_$'X@7&C6L&N_
M%3XH:QX#^,'_  EOCS5KNS .>O\ PB>G\CPKX4L] \)@XTVO\\&@#_?XHK_
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M6GW-+^&OD?Y<]?[>G_!)C_E%E_P38_[,%_8X_P#6=/AO7^(77^WI_P $F/\
ME%E_P38_[,%_8X_]9T^&]!9^@E%%% '\%?\ P?'?\B?_ ,$W?^PY^U?_ .DG
M[-]?Y[=?Z$G_  ?'?\B?_P $W?\ L.?M7_\ I)^S?7^>W0!_O\5XM\8OA#\.
M?V@_A=\0/@S\7/"MEXS^&GQ+\,:GX3\;^&+\,;#7]!UBU^QWEJY7%]@@L=+O
MK'&7*X^9<U[310!_BS_\%</^"9GQ*_X):?M9^-?@#XK@O]<^'MY<3^,?@/\
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MP_'[^W_ ?Q-\+:!XX\#:Q_PCG[-/QU\1Z2/$/A3Q/8ZAH&M6>GZ[X?\ #^O
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MSG_\[FC_ (=-_P#!+3_I&[^P7_XB#^SG_P#.YK_$5WMZ_H/\*-[>OZ#_  H
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MMSH^J#6=*U/2M8\+ZYX=\1:)K>G7OV5E\0>'O$FEZID%"R[M04_E+_Q"Y_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b4_001.jpg
<TEXT>
begin 644 form424b4_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #' M # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MDS2T %%)2T %%%% !1110 4444 %%%% !124M !1110 4444 %%%% !1110
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M4(()+J5(H8VEE8X5$7+$_05X7\3_ -HY/#MY>:-X?LVDU*!C%-<WL9186'!
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MIMY<Z=I<\5G/+ -.3,L<1*C&<Y(&*L_\*\\4?] &]_[X'^-(/AYXH[:#??\
M?/\ ]>OY]^JXV;J.IA9)2M\,6K6^3/U#VV&@H*&(C[M]W>]_FC=N4D;5[Q63
M4UBEM-@EG;_0DS /F([J.WO7.>%W2WUS3C;7DC&3(F388P/E/!.?F%3?\*\\
M48Q_8-]CTV#'\Z/^%>>*/^@#>_\ ? _QKMQ"QU:K"HL))<K;V?7T2_4Y*,<+
M2IR@\1'56W71>;?X6+.D"[,FA-;&0:*L(^U8_P!2.3YWF]LD>O/3%26 N3<:
M/) 9!H*VV+C!/D@?-YHD[;OKS]W%4_\ A7GB@#_D 7V/38/\:3_A7GB@C_D
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M*_B']K;X@Z#=>/==-KX.E\)^#_%S>'KC3&EF35KR'S8T#Q?.5#XD!'!#%6
MQ7T+KW[/OPX\3^)9?$.J^#-)OM:FEBN)+R:W!=Y8R#'(>Q92HPW7BN6\(?LG
M>!M"\8:]XIUC2+#Q+X@O_$-QKUKJ%]9KYMD9=I6)#SD(5)!/.6- '%Z/^TYX
MKU+QK9_#AM,TQ?B$/%,EA=Q>5*L":*L7V@7X0ON!:)D0 MC?GC'%?3U>3?#K
MX#MX4^)VO_$'Q!XAD\5>*M2M5TV&[>RBM5M;)7+K$%C'S-G&7/)"J..<^LT
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M=$E94P Y4#D8!R3CFNUU#4YKC6O[%MT5&:V^T2SR<A4+;<*!U/7V'O7'^#?
M,_P;T:_:TU.XUVS8QN8KYL211I&J;4<=1P6P1WQFF!Z-:VL5E;16]O&D,$2A
M$CC&%50,  =A4M(K;U##H1FEI (>E?('QE_Y*?KO^^G_ * *^OSTKY ^,O\
MR4_7?]]/_0!7Y1XB_P#(MI_X_P!&?H/!7_(PG_A?YHXRBBBOYV/VP[+X-RL?
MB7H:9^7S6X_X U?8 Z5\>_!XD?$W0/\ KLP_\<:OL(5_1/AU_P BRI_C?Y(_
M$N-5;,(?X5^;%HHHK]69^?GY1?\ !3__ ).-L/\ L 6__HV6O$OV?-1NK+QC
MJ=O9V6O3W%_I,]FM]X9MOM&H:;NQ_I$29&<8VG!!PQP:]N_X*?\ _)QMC_V
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M=]R2_+C>=QY'I7O]% %'1-&M/#NC6.EV$*V]C90);P1(,!$10J@?@!5ZBB@
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MPO#O@GS]-\,K'XFUI?E,J-BT@/\ M-_&1Z+^=?'/C[XD^)/B9JAOO$6IRW[
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M/2\@:9M17^T]DLK,#\@16&U#R00_08H ^@[72;&RB6.WL[>"(/YH2*)5 ?\
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b4_002.jpg
<TEXT>
begin 644 form424b4_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +- M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF[_ &-
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M&(QW]ZD!]:KJ^5'I4H;/!H EHIJGMZ4Z@ HHHH **** "BBB@ HHHH ****
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M<4 ,F?!'K55Y"S[5Y8\8IT[9X[U<L+7:/,<?,>F: %LK$0_._+FKF.:!UI:
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MN>@&>E;GP@_9HT?X0?!O5_AYI][-<:?J/VG?/)]\><"&_G7L94D=*<* //\
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MH7!=_*'2F0IM H FA'7TJU&.14<(SFI5'&: 'J<MQ3Z0#@4M !1110 4444
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M%.KF_!OC:S\86+-&IMKZ'Y;FRDX>)NXQZ>]=#YG3B@!],;J?I2AMW2@KDYH
MA89/(^M5I$RI/:KK#]*A<8 Q0!FSQG((.&%:-G<K<H ?OKU%02IFJWS0N'7[
MQZ^] &N(@"*7RUY]ZAMKI;E<#AQU%3YQVH 0Q@C% C"C IP.1FEHW JWMG%=
MVLL,J[XW&"#7FUYX4UC0F,>GQ#4K/E@&;#+[5ZBXR/2HO+R#[UO2K2I;'!B<
M)3Q*][<\TT_PCJNNRQMJ2+86<;?/#G<91Z$UZ59P1V\"Q1J$1!A5'0"E,>4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*BG ,$H_V#_*I:BDYCD_W30!POP7R/"UV#VOYQ_X]7?UPGP=&WPY>KZ7\_\
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M$4 :<>G0)AMNXCN>]3QQJA.U0![4$YY'&:>I!Z4 !(%%&!G-+0 4UB!UIU%
M$;Q)(.5!JO+IT+G^[]*N44 9,VF/&<Q'<*KLTD)Q(I7W%;U,:-7R& (H R%F
M! J=)@3BG3Z4#EHVP?2J1WV[XD&TT :*2CZ"I@X _I6='-QGK5E)>.: +089
M'\ZD# U6#^G(J7/3GF@"6BFJV?:G4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %- P,4ZF Y:@#A/A4<?VXO
MI>O_ #KOJ\_^%YQ>^(5]+QN/QKT"@ HHHH **** "BBB@ HHHH ***0G%  3
MBHG;KZTK$\5&[  X.!0 C-D5!+)@FAY",\Y-4YI_Q]J '22[33[:Q>Y(9_E3
ML*DL['<1++SZ UI@ # X% #(H5A4*H &*5DR.O/O3@,4M $83:,YQBO,?B?8
MVW@6&?QOIUT--N;=<W$./W5T/1@._O7J)Z&J&KZ+9Z_9/9ZC:QWEJXPT4@RI
MH \)_9V_:(N?BWXIUNQU!8K8#][9P \A.^:^A%'/.,^U><Z?\ _".A>)[77]
M&L/['O8.UJ<*_L17HR#K0 ZBBB@ HHHH **** "D(S2T4 -V^],GA248=<U+
M2&@#'N;)K9MRY,?M38Y@0*V-N>,9'<&LV\LC$?,A'R=UH DC?&!UJP&/_P!:
MLR*7&.35M'/3- %Q#Q4BG(JO&QQBI0>AH DHI,BEH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IH()Z<TZF]&H \_
M^&1VZSXE7TNB?UKT*O._ALI3Q'XG7_IXS7H2GU]: '4444 %%%% !1110 4E
M+10 4QOO?A3F.!43<&@!C-U[5!(W!%.E<9SVJM+*-N: (IGP!CK5BPM/,/G2
MC'M45I;FYDW'[B\\UK@8QC@=A0 */R["G44T# ZYI7 =2&F,<]\<5R7BGXH>
M'_">5OKY#..D49R3[5<83J.T%=DRG&.K9V%%>#ZK^T_;EBFFZ3,<'[]QT/TQ
M5&S_ &GKM68W>DHR#IY1.:[XY=BI*_*<SQ5).USZ&%+7DOAC]HCP_K<RV]ZD
MNES'O-]T_2O3+#4+;5;2.ZM)UG@<95T.17'4HU*+M.-C>%2,_A9>HJ-#T[U)
M6*9H%%%%, HHI,T %&::N:*5P'9HIM%-Z"'=/>C:",'D4TG Z4ZE<9EWUH86
M\R,<'J*BBDY%;#@,,'D=ZQKN(VDI(_U9I@7(V&#5A#5"%LXP>.M68WQV- %G
MTJ2H0<<=JD4YX- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I@SNI])GD4 >?_#Y=GB[Q0O\ TU!KOP.:X+P1\GCG
MQ0ONAKO0?FH =1110 4444 %%%% !2&EIK-VH :6SR>!43/@D#G-/)R![57D
M;!ZT 12'&>*J$&9PBCYB><5),Q&3GBI]*AR3(PY[4 78(!%&%_.I<<8I .?6
MG4 %1%P 2> .]2UY9\=/'S^$O#YLK.4Q:C>#:CK_  CN:TI4G6J*$=V1.:IQ
M<F<E\5_CI*MS<:-X=8 K\DU[_=/<"O#96>XF:69VEE8Y+R'))I%!YW#<YY9C
MW/K2@@=#GV]*^^PV$AA866Y\S4KRJN_07)SD]:0]\<$]303Z<THSD#'/6NY/
MH8N[U&LH<'(R:Z7P;\1]:\"W7G6,GVBV(P]K*24 ]17-^X'-*0> #M]?>LJM
M*%5<M1714)RA).+L?9?@;QI9>.-#BU"T8*^ )8CU1NXKHPQKXZ^&?C2?P/XJ
MMYTE(L9V$<\1^[@GK]:^OX+B.XMDFC8-%( RMGC%?"8W"O#5++9['T6'KJM&
MY9I,FN?UOQ]H'A[*WNIP1N!G8&R?TKE9?V@/"L3*//=@QQD+Q7-"A5J*\8MF
MTJL(NS9Z52,< FN-TWXP>%M2F6)-4B1VZ!^,UI^*?&VE>%=&;4;RX4P'A GS
M%SV Q4NE4B^5QU&JD&KIFT)E"%F(11U9C@5@:Q\0O#^A9%YJ4*NO55;)KYH\
M<?%W7O&D\B+,;+2P2%@B.-P[$GUKB6!D?=([2-_>9B:]W#Y-*HN:J['FU<>D
M[01]8K\</"+7'E?V@ W7..#6]I/C_0-;DV6FI0N_3:6P:^,-@P0 !Z'%"H8V
MW(6C;/WD8@FNJ624VO=EJ8K'S3]Y'W:9,)NQGW[5(IW &OE#P5\;?$'A:6*"
M]G.JZ=N"L)?OHO\ LU]+^&/%FF^+-.6[TV=9HR/F ZJ?0UX&)P=7"_$M#TZ6
M(A5VW-DC(J*YMQ/"4/X5*&!I"<\#@UPMG28<9,;%#U4X^M6X7)%)J< 0B<<=
MC443X4<]:8&BI^[Z5+G'2JL;#BIU))()S0!*#D4M-4\?2G4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28&<TM- .: ."\
M(G;\1O$R#H50UWJ].:X/PR-GQ0\2KZQ1&N]!% "T444 %%%% !1110 5&W4_
M2I*C8\-Z4 1DX4?K5:5LM^%3N0 2!UJI*PZXH K,IF98QU)K;C01QA>P%9>F
MQ&2X9^RUK#..:  8%+110 AX!)KY$^,^NR:[\0[QGR8[0>3$OMZU]<3Y$,A'
M7::^)_%\LD_BS56F&'\\\CTKZ#)H*59R?0\S'2:@DC)*DYSP?05FZQXETK0E
M'VR[1'[1@Y-8WQ!\8CP[8"WMF']HSK\O^POK7BTC-<2--.S22L<DN<FOT+#X
M/VL>9GRM6MR:(]E7XL:$TFP></\ :(XKH-(\0:;K\;'3[M+C'WD!P0:^><<=
M!BI;"]N-*N!<6<S6\BG.4Z-[&NR>!C;W3&&)=_>V/I =>*"2,8Z=S6!X*\3_
M /"4:,)R!'>1_+*@[GUKJ-*TJ36M2M["(A&E."YZ+ZD^U>'57L;J1Z47SV<2
MYH'ATZY))+<2BRTJ [IKI^, =A[UTWBGXLZEJ-I'I6CW#V>D0((ED4_/*/4U
MC^--8BNG@T6SV)I^G#9F/I,_=CZUSH QZ#T%>=[%5VIU%<Z/:.FK0&+'D@R.
M[N>=TC%C2[44C[J^^*4C/3K1C(Y KN2BME8R;;UD)Y2$GC;SG<.*V-#\4WVA
M*(L?;[+!4VMP=RX/4C/>LC;CBE/M^E9N$)[Q&IRCL=-JNA:7J]D=2\->81$-
MUU8.?F0]R!Z5S 8.,^M6](U6XT#48M0M"%F0X*'[K+W#5H^-(]-MY+;5[,K:
MV-^-QC<XVR=P/QK*//3ER/4J5IJYB49S38G65-RN']2ASBEP.QR.QKK:L]3%
M"GI74?#;QY<?#WQ"MS$&>PG8)<PYX(_O#Z5S%,/Y\8(K&I2A6BX36C-(3=-J
M2/N?3[Z'4K.&ZMV#Q2J&4@]C5E3EB*\B_9P\1_VGX2GTV1VDN-/DVL6/4'IB
MO7(QAB?6OSFO2]E5=-]#ZBG/VD%(2: 2PLA'7I6-&#'N0]CBMT]*Q[Z+R[L$
M#Y361J6(VY%6D/K5&%C@5<C.Y><&@"9>2:?4<?45)0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 44F>?:EH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;SNQ3J:.230!P6@
M';\6_$:Y_P"76$UWH'S&N T-O^+Q>(1_TYPUWZ_7- #J*** "BBB@ HHHH :
MQ(4XJ-\A?YU(_P!TU'(>"/QH @D)P?:J4S$ YJW*WRGWYJA<'VS0!H:5'M@S
MCK5ZJ]JFVV0=.,U.IW#- "TG2EHH :PW CL1BOCOXIZ,^B?$'4(&4A)9/-0M
M_$#7V*37A?[1W@U[F&T\1VT;-+;_ +N? SA/6O7RNO["NK[,X<73YZ?H?"'Q
M'NVO/&5\KGF ^6/85SIZ_6NK^)VGM9^*9+C;F*Z&\/VSZ5R@'?D?6OV/#VY$
MX[,^!J?$TQ#DGVHQ^E!YZ4%L>WUKI22,SM_A%>-%X@FMPWRR)D@]*^AO"\_]
MA^&M;U?"B>=?L4)(^Z?45\_?"*P>75;N[*E4B3&2.M>_:@_D?#_3T/+37&\>
MPKY/-+3J*)[>#3Y+G,0K@?-DG'/J32KD^Y]/2E +#'05YCX\^(]PETVG:1-Y
M(3B691G)]*5"E*I+E0YR]G[QZ/=ZC96#8NKN.%CV+4MO?VMYC[/<12D_W6KY
MREDEN&9IIGE9N268FG6MW<V4J26UQ)#*O*N#]T_2O3_L[3?4X?K=W<^DL8)'
M/OFC !K@/A]\09=8D_L[5)-UW_!*>-WM7?$'/3KQ7EU:<J4[,[HS4U=!G/:G
M:WHL7BWX;>(=*D+_ &JQB.HVS@]-O\(IO.?6MGP@ =;-NW*7<+P,G9L@\&N6
M;MJ;:/0^8-!\3:GH\D5U;W#,0/FCD.0?45[/X/\ &$/B^Q\Q46&Z3B2$=O<5
MX;=1_9M3U*)1@Q74L>WM@,:V_ FJR:3XGMF1B(YCY;+7TM:@JU)31X].JXSY
M6>[-DXQQ1Z4ISW[T@^7@<G^5?/VM[IZNYZQ^S7>FW\97MJKG;/"7*]CBOI=1
MR#7S7^S1:+/XKU&ZR"T$6SCMFOI12<BO@\TM]9:1]'@[^Q5QU4-63=$' Y!K
M0JK>KNM7]J\L[BA"<X]^U7D. !C%9MNWRKQ5^,\X]J +*'-2*<BHH^]2KTH
M6BBB@ HHHH **C$HSC'/I3@X)QWH =135;=3J "BBB@ HHHH **** "BBD-
M 3@4W.>]*YPN>M-'(S0+38<.E*.E(HP.:4<"IO<8M%%%4 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYI:[/C+K!
MZ;[.+\>*] 4XP#U->?VY\OXR77_32S7]!7H*Y.#Z4 .HHHH **** "BBB@!K
M_=-12Y'-3-]TU%-]R@"K*<#DU0F(,B]P35^X[5GR_P"N3ZB@#<48C QVJ2D'
M04M !1124 !JM<VL=Y;R03QB2&0%65AD$&K)X%-R30)J^A\<_'[X 7D;W$EI
M;O-IA)EBFC'^H]C[5\H:OH-]H%RT%W">.DB@E6%?KA<0QW$30S(LD3C#(PR"
M*\C\=?L[Z)XB2:XLV6QFY;85!0_7T%?9Y9G[H)4JVR/ QF6JH^:F?FV6&<8;
M\JU]"\(ZIXCF1+>W9;?/S3N, "OI:3X-6D=Q*;>72;L*=H\E\Y-6X?AWJL,>
MS9;VL0Z*6 'UXKZ^>;0G!.!X<<'*+]XX_0](M] TFWL(,'8OS2$<L?>NSD7[
M5\.8I$R5@NMCGKS3W\*Z/I,>_6=;CG?[P@TOYRWL<]*TM$\266L6U_X9MK!;
M"TOH\6[MU$HYRU>!6KNM+GBCTJ<5"-CS'Q1?G3?#U[=(V'2,@'TKY^63>6?)
M/F'))KW[QEIDMSX=U&Q92LR*4*X[BO $!"A",,O!'I7U&7-.%SR,5=2 <YXX
MIQ.,<<"FGBG=*]BYP.R);6Z:RO8+E#M:-PP(KZ*L;K[986TX_P"6D8;\:^<8
MH3<SPPA26D<*!7T9IL+6VG6D)^4QQ@$?A7C9ARO5'?A;D_\ %6OX9D%K-JEZ
MS!([*QDF:0]$QW-8^<9SQ57XCZW%X/\ A/>6[;AK&NN(XD[&W_BKPFKM16[9
MZ+TNSYU>;[5<W,X;<LLSR!NQ!.<UI>&;9KOQ%81J,D2!N/2LJ,"&..,9)  "
MKZ5ZI\,/!;6\?]K7\?ES-_J(CU ]37U5:4:-&S9XU.+J3T/1F]!UICN$#$G"
M@9^II68EL]*Z[X7?#^?X@Z^JD-'IMJV^:4C@GL!7R-:M&C3<YL]VE!SDDCVO
M]GKPO-H7A)[VYB$=S?-O(QSCM7JJ#YL^M16=M'96L,$0VQQJ%4>PJ<=:_.JU
M5UZKJ/J?44X>SBHH5ONFHY1NA<>U/;[II&_U9^E9FAB0D XZX-7XR-V>U4$&
M&;_>J]$.A/&* ,/QY\2O#'PJT)M:\6ZS;:%I08)]JNB0F3T'%>;_ /#<7P'5
M-W_"SM"P.WG'/Y8KU#Q9X'T'X@Z3_9?B32[;6+ L&^SW2!USVXKX5T?X$?#Q
M_P#@H?J^@'P?IG]C+H2R+9^2#&'V\MB@#[L\"_$'P[\3/#T6N>%]6M]9TF4E
M4N[8DHQ'6NASGI6%X4\':+X%T>+2= TV#2]-C)*VULNU03UXKYW_ &E?V@_&
M=C\4O#WP=^%=M9MXTUB%KFYU*_)$5C !G=[L: /J7(%!Y%?(.H?%_P"+G[*W
MPH\9^+?C-<:3XDTZP1(](ETK(FFG?A5D'9<UX;%^V7\6/A[;>'OB%XD\7>%?
M$>AZG=0Q7WA'32QN;6.8X79QRR]Z /OR/XM^%7^)DGP_&K1'Q=';"\;3_P",
M0GHU6/ GQ/\ #7Q,357\.:E'J2Z9=O979C_Y9S+PRGW%?)>ASV^I_P#!3VXU
M&&,!+GP=;S([+ABK+D#]:Z'_ ()U1JFE?%W:H!/C2]S@=?FH ^OEX]?K3J**
M "BBB@ HHHH *3O2TE "&11U8"D:1<<D5&V.2>QKG_%_BZQ\'Z;)>WSKT_=Q
M _,YKDQ.*IX2E*M6=HHTITYUI*%-7;+?BGQ=IWA/3VN[Z<1H!\JY^9O8"J_A
M/QGIGC.Q^TV$P<=&C/WE/N*^9_%FOZOX\N9=7N(W_L^(X5?X$%5_"NL:MX-E
M36K%'^R%]L@_@8>A]Z_&I<?U/[0Y(TG['OUMW/NEPROJG/*HO:=O/L?8.X8[
M8IRD$<=*Y/P5XTL?&FFI<VKA9 ,20L>0:ZJ/IZ5^QX3%T<;2C7H2O%GPU6E.
MA-TZBLT/HHHKM,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#SJ<B/XR0?]-+0_H*]$'/2O/-4&SXQZ4?[]J_\J]#
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M@LI$M;C5Y5_T1XUX,P/]['-?H(S<C@D5 -0MIKF6VCNHFN8@#)$'!9!ZD=J
M/F#2OA!XMC_;QF\?RZ=%'X7;PU#9&=#PLX7YD7V%;'[%OPM\1_"[3_B-%XCL
M_L;:IXGNK^U_VX7.5:OHL3(\>Y9%\ODEPP('XU3T[Q!IFLRSQZ?J-M?2V[;9
M5MY5<H??!XH T48MFGU'YFWM09,=,G/3% $E%1^9Z<YH\SCJ,T 245$TI5<L
M5 [DGBA)A(N596!Y!!R#0!+2&F;F&.G-(TA5?>@"K?7+6MG<S)&7:)"RKZX%
M?.=IHWB'XQ>*I)-0BELK*-\'=G"KGH!ZU]*L@)(YYID%HD))4*N?[JXKY;.,
MD_MB=-5:C5..KCW/5P./>!4W"-Y/9]CR_P")_AVS\+_"VYLK&(1QH!SCDGU-
M4/@EI-IX@^'EU:7D(EB>4JP8=..HKHOCH!'X O2?:LW]GT;_  9*>@,Q_E7R
M$L'0CQ-'#J"Y/9VM\SV?:U'D[J-OFY]_D>>:YX6UWX0^)(KW2?-NK-G^4(,A
M@3T:OHK0+^34M'M+J:(PRRQAFC/\)]*GDMXY4"NBR#T89J:-55,*,*.@%?6Y
M1DD<IJU'1F_9RVCV/'QN/>-C#VD?>77N244@XI:^K/)"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._$/[OXP^&CC
M[]M-_*O0DZ5YWXM;9\8/!G^W!<C_ ,=KT4$$XH 6BBB@ HHHH **** &O]TU
M'(.I]1BI&^Z::W*F@"JXP #VJC.O4]JT)%ROTJE,N01^E &C8OOMD/?%6*H:
M5+NC9/[M7Z "BBB@ IF,XI],ZTF Q3AL'UKY>_:&@,?CY923S#P#T-?4#Y !
M'7->$_M,Z$?+T[5UP%4^4V*]7*YJGB4GU.+%QO2;/EWXF^(Y?#^BK';D&>[/
ME,?[J^U>+!-I]1UYZDUZ-\:0XO=..<Q&/\,UYU]:_8,%%*%SX7$-\P<GFCG/
M3-&.U -=R;M9G.==\,->;1M>%K(2;6Y&S;GA3ZU[.PR=F0W'WB*^=]##G7+$
M1G#^8.:^B2.%R1G KP,=!1E='IX:3Y2>QU6^TJ57M+V:+:,8+DK^5>K?!OQ'
M?S:C>ZGX@N86T"VA.)+B)>9/8FO._#'AV/7'NKN[G\C2K%?,G(ZO_LK[TSQ!
MXHF\0I';(HL]+A_U%JG"X[%O4U\UB*4<1^[@O4]:G/V;YV>OZ_\ M'VEG++#
MX?TU70#'FLNT$^M<)?\ QP\87LC,MZMLI'W47.*X/@8VC QSQTI<X/K3I9?A
MZ:^&_J$L35EN]#MK3XU>,+1 &U$7#=077%=OX9_:5FB*0ZY8@CH98NOU^E>)
M']*#[C.>]%3+\/45N6PH8FK%W3/MGPYXGTSQ/:?:M,O([N,XW;&R5..AK5W[
MCQS7Q'X8\5:EX,OUNM*G:,ALO"/N2?45]:> /&UIXZT.&^MF59<;9X<_,C5\
MGC<!+"/F6Q[5#$JKH]SJ5X!IPZ4WK3Z\M:ZG:%%%% "$X%5;U]EHY[MP*MUF
M:M)G;'VI@5X>@!J\@Y '6J<2\J,<BKR<,* ,3Q_XM3P!X#\0>))HO/BTFREO
M6C'\812Q'Z5\9Q?\%+=9G\/:3XP3X.Z^O@";'V[7&C.V%2<%U]5]Z^I?VDE+
M_L]_$9>A.A7G_HIJ^!/ ?[5&C:K^PUI/PL\/Z!K&N>,M6TLZ/!:+:$QAG.-Y
M;IM'6@#ZR^.'[;?AGX+Z'X UR/2KWQ)I?C'_ (\O[.7=*P(!4!>YYQ61;?MS
M?V/X&\2>*/&GP\U[P=#9SQVVCZ??PXN=6DDX18E]<XKQ;XI?##7O 5M^R5X9
MNM.EO;S19ECO7A3>D+8!.[TQG'X5Z_\ \%#O!?B'5O!W@_Q9H6FRZU'X3UF'
M4[RPMUW2M"K LR+W( H ?\//VV]5_P"%@Z)X7^*7@"_^'A\19_L>_NL^1(_:
M*1C]USQQ7.^!+MHOVQ_VCX[ZYN9-.B\.6\C0+*?E7:22@[''I7GOQW^)\?[;
M_P 0/A'X6^&^E:BXTO5HM<U74+^V,4-E'&03&Q_OG!&*]$\-:3J'_#6W[2=V
M;&=;:X\,01P3%#ME81D$*>] 'EOQ6^*TWA7]@=;GX<66K36.K:LUC<7$\[//
M;JSX;YB<C/05UGP+^('@S]D[X(R^*]1\!:SX;US4Q%:P6-Q<O/<ZQ.?NE QX
MR2*XRYT75E_X)S1V:Z3>B^_X26-C:K&?,V^<#NQZ5WO[=?POUSQ?\)_A9XI@
MTN]UO3?#+PW&J:?99^T^454%T _B7% 'H'PM_;3U;5/BGHG@;XD^ KOP'J'B
M&-I-&N)7#13$#/EL<\/[51\3_M^M8?$3Q/X$\._#7Q#XO\1Z'<"&8:9#OA5"
M<;G;M7E'PTO?@!XZ^,O@-]/T_P <>(?$B2B?3WU 2-%I[]_-+?=KUS]D;2]0
MLOV@OCE/>V$END^I QW#I@3#/8]Q0!>\=?M2_%'1M2CAT#X,ZC>VRV2W4]Q>
M/Y0SC+1KSR16!X__ &LY/BS^Q7XW\<^"M*O['6K 2Z?=V3C;-93J/G;CL/6O
M#_'?C@_\-+^/X/CN?&":/;G9X8T[0S(D$L7JI7JQ%:_[*O@34_$/['/QWTC0
M])U+3O[3U&]?2[/4E*W#1E<J&SR2: .U^!7QR\3_ ! _94GM_'GA75;+0[/P
MR)I/$.]E:_X.2AZY/K7?:'^TIX,^ W[*'@7Q%;V^HZBNL0K!H>CNQEO+R4DX
M0$\G'<UYG\'?C3IOC3]C+5/AE:Z5JUKXO\.^%VM+VSO+8I^\52,*>^:XWQSX
M2\4Z1^S%^S)X]LO#\^HP^!+@7>K::D>ZX2)B5+*O<B@#Z(^%/[9&JZO\1M+\
M$_$KP)??#_5M<7=H\\^3!='&?+W'H^.U<QXD_;YUN7QYXW\&>"OA=J_BW6_"
M]X]M/+;K^XPO<MV)["N.\=_$N#]LO]H7X-6G@+2M2;2_"6H'6]6U6[MS%% I
M4#R@3_%QTKMOV+=+U#3OV@?VBYKJPFM;>Y\1%X9I5($PQU![T >W?LX?'O3_
M -H;P!_PD%K83Z1?VTS6>HZ9<#$EM.OWD->L+D 9KY'_ &"M*U#3-<^-AO;.
M>T2;Q;-)$)5(#KC[R^U?7"C H \^^.?_ "(-[D9'%9?[/N/^$,F(Y_?'C\*Z
MWXC^%IO&'A:[T^W<1SR#Y"W3-9WPN\&S^!_#HL+F027#MO<IR!7P<L!B'Q&L
M9R^YR6OYW/?^LTO[*>'YO?YKV.T4@\]_2I(S\O2F*. <<U(F,=,5]S%'S^O4
M6EHHJQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$@4
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M:@>:HBY8X R3VJW;Z6S$-,<C^Z.U %0,\S;8T)/>K46F.3F1\>U:"1+$ %4
M4\#&<\T 01V,,>"$&?4U.% Z "EIH?=QTH \\^.!V>&],?TU2V'YM7HFT$YK
MR;X^>)=,A\.6=HU_!'=IJ=JS0LX#!0_)QZ5Z9I6L66MP&XL+J.[@!V^9$V5S
MZ9H O4F,4M% "8I"N?0_6G44 02V<4F25 /K5273"HS$W/O6B>E Z4 8;++
M3YBGZBGQS@@=ZUW0.N& -4+C2P6W1'!_NT (DV?I5A'#<DUF>8T3E9!M(J>&
M7/U]* +@.>#2G&TXJ-9 PSG!J3>* (W3<.E5)8^&R./>KS]!4;H&4]"* *=O
M=-9R8)+1FM:.994W*<BLV2+J*A1Y+9LQGC/(H W <BEJK:WZ3X4G#^E6<\T
M+12=!2T %%%% ">M':EHH 8$"GWHV\^N>M.YI.>*FPCB/%7P@\.^*2TDUH+>
MX/\ RTAXS^%<!>_LQQ,K_9=6>/\ N[E[5[LRDXI&7CIDUV4L77I*T9&$Z%.;
MNT>!VG[,(#+]JU<R)_%M6NZ\-? _PSX>DBG^R_;+B/D/-R/RKT (1QCBEPW0
MC\:NIC<155I2T%##TXNZ1'# D*".-%B1>B(, 5(% -*!@^U5KC4(X3M7YG]N
ME<-M;LZ":6=($+.<5DW-PUYT^YFD?=<N7D)_W>U2QQ;1QQ37<=@ACVJ,+5N-
M .,4D<6"*F"@?7I0 J#%2*.<T@&"!4E " 8S2T44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %1DYYI6ZG-1EOQ]!0 CL2!DU!(^< <TZ5^.N*JR.>QQ
M[T ))+P3444<EV^U<@=S2V\#W4N.0G4FM>*)8E 08'>@"*WM%M5  WMW)JR*
M6DH 6BDI: "HR<GVJ2B@#YC_ &MO@Y=>*3IGB#1H9'NS,EK<QQDY*L<!L>U>
MY_#;P=!X#\&Z9HT(P88@9#_><CDUTS*K'# 'OS3L9.?2@!:*** "BBB@ HHH
MH *:1SGI3J* (9[6.X7YASZUE30R6;G/*_WJVCZ4R2-73:_(H RXI<CBK"MW
M'%5;NU:U;*C*4L<N2.: +RG/?BEV@@]JCC.ZI!R/>@"-HQDU \(VU<VG--9.
M.E &:\.#QE<#K4L%[+",./,7U-6)(\GI4#Q#'2@"[%?138 ;:?0U:K!:$9/&
M/>G1S3VX^5RP]Z -RBLM-691^\3\14\>J0N>X^M %VBJZW4+Y/F ?6G?:(Q@
M"1<?6@":DJ+[1%Q^\7\Z:UY"O60'Z4 3]:*I/J<*Y RWTJ%]4<Y")]": -,D
M 9/%5IKZ.#/S;CZ"LPS3SYWN?H*%A&>0<^] $LU[+<\+\B>U11Q8/.3GO4Z1
M8[5.D8':@"*.(8J=(A3E2I0N?I0 T+SBI%7/2E"DX[4X "@! @'O3J** $I:
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *:QQQW-*3@$TPMGGTH 1NO\ZA=
MQ]*>SXSQDU5E<$GM0!'+)U&:@CB>ZD"CD#O37W.VU>6;MZ5L6MN+>(*/O=S0
M Z*)8D"KT%2TF,'VI: "N0^*/Q*TKX4>#M0\1:O*%M[9"4BSAI7[*/K77U\E
M?\%%-#U;4?A?87EG$TNG6ER&N]O\ [$CTH \HG_X*.>*KC5EN;;PW!%IF[/D
M.V7*_6OKOX"?'+2OCSX.36M.Q;7<3^7=63'YHF]_K7Y(K*DD8=&!C(R'SQ7V
M5_P35LM2&L^,[^.W==&G\M3,XPK.!QM]: /O2EHHH CD)'3&?>L?7_&>@>$]
MG]M:U8Z69.5^USK'GZ9-3^)=3.AZ%J6I!/,-K;O*$]2!FOQW^)_C75?BGXQU
M/5/$-S)>DSL(K=W)2%,\ "@#]B-$\2:7XGMC<Z/J=KJ< .#):RK(H_$&M0=*
M_)7]F;XHZ[\+?BAHMOI4\C:7J%PMO<:?N.PACC<!ZBOUJ4Y4'ID4 +1110 4
M444 %,<D' [T^HI5+[E!VDJ0".Q]: /DC]I;]MN3X:>*I/"WA.RBU+4;<$7E
MPY^2%_[OU%<7\'_^"@>I3>)+#2O'&GQBQNY1"=1@&#&Q.!E>XS7S;\?_  W?
M^#OC7XJL=45DNKF[:YBDD'^N0]&!KC='TZYUOQ!IFF:?&]QJ$]P@BCC&YNOW
ML>U '[61R1W<*LC"2*10R,O(8'O69<P-:R_],SWJ+P1IUQHW@W1;*[D,MU;V
ML:2.1@DXYXK9EA6>$HPZ]* *$4N<$''M5J-\C\:S1F%V1N2*MQ..* +H.1FC
M!/:HT.[\:F5LY[4 ,9..E1LG(XQ4Y/3N*3;D\?K0!59 ?X?QJ-HMHR5S5QH\
MGK32G:@"B\7&<<>E1M![5H&+--:+% &>8 1R.*;]G7/2M'RR:3R30!GBW'I3
MA /2KWDFE$1% %)(?]GFI!"<=#5H1\_K3UC- %98L?PU(L>.WXU,$"FG!,C.
M: (PF>U2!#TIX'/'-* ?I0 T<9]:D"BA1CZTM !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4QN>*?3#]XT 1O\RFJLIW<59S\AJG<?*I_I0!5&)+E%]36X$
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MTR_@OGLY/)N%@<,8G_NMZ&M,.5'(H DHJ/?[TWS"3T('K0!-146_CK2&0@D
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MU8S0^:PP\I,C?4]:FH **** #'%&*** #%%%% "$$%67AU8,I'8CI7NW@_\
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M10 4444 %%%% !1110 4444 %%%% !2$9I:* (6'RDCK4$@X]JLXQFH6' H
MSYDY;UQ5O3)?,@*9Y4XQ4,JX)/7BHK.7R+G)Z-0!LKG'-+29X'O2T -?.WWK
MQO\ :UTQ]4^ WB1(TW-'%YGITKV.0X'I7FW[0WBO2?!OPBU^]UN(7%E) 8/*
M)QN=@0!0!^15D=UI$>^T5-35*LTC(NR-G+(G]U2>!3J "BBB@ HHHH ****
M"BBB@!".?ITKK_@[XEF\(?%;PUJL3E"ETD3;>X8XKD:O^&K-]1\6Z#;1L4D:
M^B((Z\,* /VFMI5N88IE_P"6B!A^(S4U4-(C:WTNQC/)6!%.?H*OT %%%% !
M1110 4444 %5-0G\JW;'5A@5:.>,5DZA-YUP$'W5H AMU(VXZU?C4 C%5HDP
M!Q5U!@@T >;_ +2G@C5?B/\  ?QMX;T64PZK?Z=)' RG!+8SC\<8_&OEG]E+
M]L3X=?"K]GSPIX'\3VE_I/BO1"-*NM'&G.6:?S"-PXP0<YS7WD5)((.!65/X
M,T*XU$:C+HMA+?CG[0UNA?/KG'6@#X[^"%O]J_X*)_%2\DT^58YM$@>*XF@(
M3:64@!B,9^E>>_M8>%K7P9^VEI?C'QMJ_B30?!^HZ-]DLM>\.J2UE.&_U;X!
MPIQFOT7CT^WBNFN$MH5G8;6E5 '(]":BU+1K/6;9K;4+.WOK<_\ +.>,./R-
M 'PS^SMIWPPMO'GQ \7?"[Q!XH\<_$&'1Y-]WKH;R9R =JJQ R<XKY7\1>./
M#GQ$_9U\7W_COQMXTU7XK7@E27PMY#_9H9!+A45 N-H'?-?L3HWAG2O#MOY.
MEZ;:Z='W%M"J9_(<U67P1H"ZA+?C0M/^W2C#S_9TW-]3B@#\]OBE?3^$OV<O
MV6?%E[87C:5X?U:"?4EBMV>2"/;C)7&>,&N]_:B^(^B_&6]_9_\ $OA(W.JZ
M,/&$1:9+9U*<=6!' ]Z^W9M)LKFT-I-9P2VA&/(>,%/^^<8J"S\.:5I]K%;6
MVFVD%O"V^.)(5"HWJ!C@T ?"EOXVMOV7?V[?B/KGQ @FL_#?C*UCGTO6EMVE
M2/8H!B) .W.*XW2)[OXB^'/VK?BAIVE75IX1UNR\C3#]G9'OMH ,FS&37Z-Z
MWX:TSQ+;^1J^FVNI0@Y5+B(.!],U8ATJTM[%;*&S@BLPNW[.L8$>/3;C% 'P
MWXHM'?\ X)8M#'ITHF.B1@6R6_[S.\?PXSG]:^K_ ( !O^%)>!@ZNCC2;<%9
M 0P.P<$&NX_LZV:T^RM:P_9CQY.P;,?3I4L<"PJJ1JL:+P%48 'I0!)2T44
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MPF.E+2#TI: "BBB@ HHHH **** "BBB@!,^E>X_L;?#!OB3\8+>ZE3.FZ/\
MOI=ZG:[=@#ZUY_\ "3X2ZS\:_&">'-%D2VD*[Y[J0?+"GJ?>OU(^!WP;TCX)
M>"+70=-"RS*-]S=$?--(>I)]* ._48VX'RXP!Z5)24M !1110 4444 %)2TQ
MCC/YYH CO)Q!"6[]!63"NY@6/)YI]Y<?:IOE'R+Q4D"8Q]: )HHQ@$584989
M&*8B\<U,HYSWH =_$*?2*,"EH 3%+110 4444 %)BEHH *2EHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M76(@ _A3UCXZ58\L;L4[8 : (DB]J>J=L<T[':GA0* &[2/2G+SQVIR]33J
M$  I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b4_003.jpg
<TEXT>
begin 644 form424b4_003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (? M # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %%%% !36[?6G4UNWUH =1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UNWUIU-;M]: '444
M4 %%%% !1110 4444 %%%% #6^Z:\$_:]\3:UX=\#Z)!I&KR>&H-3UFVLKW6
M8 -]M [88@]L^IKWQNG3-><?'7PKXC\8^!IM.\-C2)KHR*TMKK4'FP3QCDKC
ML3V/:HD-;GQ/>66M^"/&-Y%>_&/7]0GT/Q!;0QZ5<7"9U.UE&047JW;D5^B]
MK();:!P&4-&K -U&1W]Z^(Y?BSX TWXQ>$[7XI_#BQM/'4!2STO4-&D%ZJX&
M%W*GW .V>E?<$;!T5AT8 BKO[J%:S):*:S8''6@$]Z '44QB1TYH+$=<4 /H
MIH)[XI<T >+>#_\ DYKQA_V"H?\ T.O:J\5\'?\ )S/C#_L%P_\ H=>U4 %%
M%% #64L,9Q7DGQQ_9MT#X[SZ1<ZM?7VFWNEN7MKFPDV.I->NT5<)RIOFB]2)
MPC-<LEH?$&D_#FX^!W[7/@/0M+\4ZQJ>FZG;S27,&H3;PQ"G%?;H.#7RK\5A
MG]M[X7X(_P"/.?\ ]!-?5/\ %^-;XA\W))[V.?#I1<HK9,?1117*=84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !36[?6G4UNWUH =1110 4444 %%%% !1
M110 4444 (PR#SBOFK]H;7M8\5^&]7T>;P]K$5I9WT A.F7C6TM\IZA7'05]
M*MR#7DO[21\#+\.7;Q_J-UIFC).ACFLIVAF,W\(0KSD^E1(I;GAWPOU>7P/K
M6G6>G? FZLO-F"2:M?/Y\Z _Q&0@FOL:/YD4XVDJ#CTKX@^&.O\ QAE\::/!
M\-GU;5OA[YX^V?\ "9P^2Z0]S%)R6XK[?4G8,\-@9QZU?1$=3Q7]I?XD>(/"
M=IX8\,^%)8[3Q'XJOOL%K>S+O2V &YF([\9KG?A;XQ\7?#KXU2?#+QAKJ^)K
M>^L1>Z=J7DB.17_CC8#J/0U:_:RTC4]/G\!^.[#3YM4M_"6J?;+RVMEW2M$R
M[25'?&<UR7A3Q#'\8?V@YOB7IUE>0^$/#6D,JW4\)5KF4@EU0=\41L]P>QUW
M[4/Q?U3P7J7A;PEHFL6GAR]\1/(9M9O &6UAC +D*>K$'BN/\.?%WQ3\//AC
MX[UY_%VF_$/1+"(#1-0@"K,)R/N3)V&>Y]*R?V@!IWC[Q1\)OC"V@7FL^$=#
MFG2_LGAS+&'P%=H^X&.:Y2Z\"S_&#4/BMXB\!:--IGAB:P0VEOY/DQZE<HN0
M40<#IUJ4M"]+G>:;XN^)7P@USX?ZYXI\3Q>)=&\:7,5K=6(MQ&;*65=RE#Z#
M.*^IM2U_3-$9%O\ 4(+0O]T3R!<_3-?'UQXUE_:"OOA+X4T+2-1@O?#M[!>Z
MY)>0;$M?*7:R$^I/2OJ?QI\+O#WQ!>$ZW9M<F$80JY7'Y4WJ18\X^'VJV6K?
MM*^,I[&\AO(!I4 ,D+AE!W],BO<_.0]''YU\[_!OP#HGP^_:#\9:7H5J]M9/
MID+NCR%\L7YY-?0?V&'^Y^M,"7S5_O?K2>:O][]:9]BB/\)_.D-E%_<_6GH&
MH_S$_O"G"5?[P_.HOL47]P_G1]BB_N'\Z- /D?\ ;L\)IIM[X,^(6G:A/8:[
MINHPVT;1.0&1W 8'\*^L=,NO.TZRDD?+R0HS'U)45\V_MYP*/AIH*A?^8S;8
M_P"_@KZ,TBVB.E6&1DBWC&,_[(KKJ:T8/U..GI5G8T?.3^]^M'FH?XA^=1"T
MA/\  ?SI19Q'HA_.N/0[-1^]/[P_.C>G]X?G3/L47]P_G1]BB_N'\Z U'[T_
MO#\Z-Z?WA^=,^QQ?W#^='V*+^X?SH#4?O3^\/SHWI_>'YTS[%%_</YTOV.+^
MX?SH#4=O3U'YT;T_O#\Z9]CB_N'\Z/L<7]P_G0&H_>G]X?G1O3^\/SIGV*+^
MX?SH^QQ?W#^= :C]Z?WA^=&]/[P_.F?8HO[A_.C[%%_</YT!J/WIZC\Z-Z?W
MA^=,^Q1?W#^='V.+^X?SH#4?O3^\/SHWI_>'YTS['%_</YT?8XO[A_.@!^]/
M[P_.C>G]X?G3/L47]P_G1]CB_N'\Z U'^8G]X?G1O3^\/SIGV*+^X?SH^Q1?
MW#^= :C]Z?WA^=&]/[P_.F?8HO[A_.C[%%_</YT!J/WI_>'YT;T_O#\Z9]BB
M_N'\Z/L<7]P_G0&H_>GJ/SHWI_>'YTS[%%_</YT?8XO[A_.@-1^]/[P_.C>G
MJ/SIGV*+^X?SH^QQ?W#^= :C]Z?WA^=&]/[P_.F?8HO[A_.C[%%_</YT /WI
MZC\Z-Z?WA^=,^Q1?W#^='V.+^X?SH#4?O3^\/SHWI_>'YTW['%_</YTGV*+^
MX?SH#4?O3^\/SHWI_>'YTS[%%_</YT?8XO[A_.@-1^]/[P_.C>G]X?G3/L40
M_@/YTOV.+^X?SH#4=O3^\/SHWI_>'YTS[%%_</YT?8XO[A_.@-1^]/[P_.C>
MG]X?G3/L47]P_G1]BB_N'\Z '[T]1^=&]/[P_.F?8HO[A_.C[%%_</YT!J/W
MI_>'YT;T]1^=,^Q1?W#^='V*+^X?SH#4?O3^\/SHWI_>'YTS['%_</YT?8HO
M[A_.@-1_F)_>'YT;T_O#\Z9]BB_N'\Z/L47]P_G0&H_>G]X?G1O3^\/SIGV*
M+^X?SH^Q1?W#^= :C]Z?WA^=&]/[P_.F?8HO[A_.C['%_</YT!J/WIZC\Z-Z
M?WA^=,^Q1?W#^='V*+^X?SH#4E$J*/OC%.#JPR#FH/L,1_@/YU+' L2D+P/>
M@9)36[?6G4UNWUH =1110 4444 %%%% !1110 4444 (W0UX/^UQH'B;6/ ^
MD7?A+3+36M9TW58+M;"_*B&5%/S!BW%>\'I7E?[0L?@63P+CXA7<UGH7VA/W
MD!D#;^P^3FHET*3LSSSPY\<OBW>ZMIMG=_#6RLK.1U2>2*^5A$O<@9YQ7TI%
MEXE+##$ D>AK\\O&.G?!V3Q%X,E^%VJZWJ?BI=6B\NPADN#%-'SN\S<  !7Z
M$VY<00[UV/L&Y1V..16CMRW(ZDC0AT*L ZD8(89!%0PV%M9P>1!;Q00\_NXT
M"K^0XJSBC:#46&5Q9P" P^3&(&!!BV#81Z8Z4MM9PV<2Q6\,=O$OW8XE"J/H
M!4^T48II 5K?3K6UDDD@MXH9)#F1XXPI<^Y YJ<)@YS3L"@#% 'BW@[_ ).9
M\8?]@J'_ -#KVJO%?!W_ "<SXP_[!</_ *'7M5, HHHH **** /+_C_\$K+X
M\>"SX?N]1GTG;,L\=U;@%D93D&OECXQ?"_QE^SU)X.UBT^)VL:S'-JMO:O:W
M0 1D+ $<'TK[S=<GI7RY^W:/^*=\#J.?^)_;?^ABN[#59<RI]#@Q%*-G46Y]
M/VK[[>)C]XH"?RJ9:KVBXMXLC'R*/TJPO%<+W.V.PZBBB@H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#W[0GC*VUK6?[<NVTZ%Q<!-NU2_"X]J^C* "BBB@ HHHH :>>*\=_:<^"?\
MPNOP&MBFJR:+>:?*+VWNHQDJZ<@_I7LE9GB4?\2#4?\ KW?_ -!-73;C--&=
M2*E%IGAW[%'C'7O&'PFN'\1ZD^K:A9:A-9_:Y/O.J-@9KZ!4XSFOFC]@OY?A
M3K1/_0<N_P#T.OI;-:8G2JS/#O\ =H?G-+48:G \USHZ!U%%%, HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IK=OK3J:W;ZT .HHHH **** "BBB@ HHHH **** &OT_Q
MKXU^-5CIDOQ*U-I]$^(UU+A<RZ.THM?^ XXK[*?IS7@7[8/B36]"\!:)%I>L
MS>';._UBVM-1U: $M!;LQ#?3/K42=M2HZNQXEX0T[1T\5Z04T+XG1N+A</=R
M2^2/=\]J^Y8?]7'C(&T8!Z]*_."\TNZ\"^.+BVNOBAK=[>Z5KUJMKIDMPV=3
MM9!N&T=Q7Z/6K>;;0OM*;D4[3U''0UI]E,GJ6**3<,XS0"#TI +12=*-P]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO_'J N6:*K>;/_SR_P#'J/-G_P">7_CU 7+-%5O-G_YY?^/4>;/_ ,\O_'J
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M+]Z/+]Z?10 SR_>CR_>GT4 ,\OWH\OWI]% #/+]Z/+]Z?10 SR_>CR_>GT4
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M&D,@49/ ]S0 ^BFJ^[Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPL7S%'BFV. 1D5YK\%_VKO ]O+XJ;6?%H=&U#-L)R>$Q_#[5[6/V>?AKG/\
MPA6D?]^!2?\ #//PU_Z$O1_^_ I7H=F.U;NCG_\ AKKX5_\ 0TV]'_#77PK_
M .AHMJW_ /AGCX:_]"3H_P#X#BC_ (9X^&O_ $).D?\ @.*/W'9BM7[HP?\
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MU?NC _X:Z^%?_0T6U'_#77PK_P"AHM_SKH/^&>/AK_T).D?^ XH_X9X^&O\
MT).D?^ XH_<=F%J_='/_ /#7/PK_ .AHMJ/^&NOA7_T-%M70?\,\?#7_ *$G
M2/\ P'%'_#/'PU_Z$G2/_ <4OW'9A:OW1SX_:Z^%?_0TVU<;\7/VI/ VL^![
MVQ\.>*%;6IRJ6Z6^=['/:O4?^&>?AKV\%:1_X#BI['X#?#S3KJ*YMO!^E0SQ
M-N218 "I]12?L+:)C2K7U:.M\-O(V@:6TN3*UK&7+=<[1G-:E1*@C"A0,#@
M=J?N]JYCI'44W=[&C=[&F ZBF[O8T;O8T .HIN[V-&[V- #J*;N]C1N]C0 Z
MBF[O8T;O8T .HIN[V-&[V- #J*;N]C1N]C0 ZBF[O8T;O8T .HIN[V-&[V-
M#J*;N]C1N]C0 ZBF[O8T;O8T .HIN[V-&[V- #J*;N]C1N]C0 ZBFALD]J7.
M: %IK=OK3J:W;ZT .HHHH **** "BBB@ HHHH **** "BBB@ I#T-+24 ?-_
M[6L<WA_7/AGXW>"2;2/#6L&?4'C7<8HW78&^F37/Z9XFTSXI?M4+XPT*Z6[\
M*^&M&+W.JH#Y+.P.5![D#K7U/>Z=;ZE:R6UW#'=6T@P\,R!D<>A!JEI?A71M
M"T^6QT[2K.QLI<^9;V\"HCYZY '-).PK'@GQ^_:\T3X=>"-"NO#]Q%>:KXIE
M:VTJ67(@C8?>DD.. N<UY?/X%T#4_@'X]_X1WQ1;^/?B'=H-3UBZM6WO*R<^
M6@[*!P*^O[[X?^&=1M;>VNO#^FW$%OGR8I+5"L>>NT8X_"I-"\#>'_##RMH^
MBV&F/(N':U@5"P]#@<T(JY\E>*_'^E?&Y?@EX:\*3'4=4T_4+:^U.)$.;)(D
MVN)/0YKZ;\??"?2?B0]NVI7>I6Y@&%^PW30Y^N.M;^D^#=#T&\GN]-TBQL+J
M<YEFMH%1W^I YK85=HH;[$V/F[X(?#S3OAU\?O&>E:;=7UU;OIL,C27\YFDR
M6Z!CVKZ)^P)G[S#\:\>\'?\ )S7C'_L%P_\ H=>UTQE7[ G]]_SH^P)_??\
M.K5% K%7[ G]]_SH^P)_??\ .K5% 6*OV!/[[_G1]@3^^_YU:HH"Q5^P)_??
M\Z/L"?WW_.K5% 6*OV!/[[_G1]@3^^_YU:HH"Q5^P)_??\Z/L"?WW_.K5% 6
M*OV!/[[_ )T?8$_OO^=6J* L5?L"?WW_ #H-@O\ >?\ .K5% 6*OV!/[[_G1
M]@3^^_YU:HIW"Q5^P)_??\Z/L"?WW_.K5%%PL5?L"?WW_.C[ G]]_P ZM447
M"Q5^P)_??\Z/L"?WW_.K5%%P*OV!/[[_ )T?8$_OO^=6J*+@5?L"?WW_ #H^
MP)_??\ZM447 J_8$_OO^='V!/[[_ )U:HHN!5^P)_??\Z/L"?WW_ #JU11<"
MK]@3^^_YT?8$_OO^=6J*+A8J_8$_OO\ G0;%?[S_ )U:HHN%BK]A7^\_YT?8
M$_OO^=6J*0615^P)_??\Z/L"?WW_ #JU10%BK]@3^^_YT?8$_OO^=62<5P/Q
M"^-.@?#;4+2QU+SY;RZYB@MTWL1ZXH"QVOV!/[[_ )T?8$_OO^=>3_\ #3OA
MS_H&ZK_X#&C_ (:=\.?] [5?_ 8T!8]8^P)_??\ .C[ G]]_SKR?_AIWPY_T
M#M5_\!C1_P -.^'/^@=JO_@,: L>L?8$_OO^='V!/[[_ )UY/_PT[X<_Z!VJ
M_P#@,:/^&G?#G_0.U7_P&- 6/6/L"?WW_.C[ G]]_P Z\G_X:=\.?] [5?\
MP&-'_#3OAS_H':K_ . QH"QZQ]@3^^_YT?8$_OO^=>3_ /#3OAS_ *!VJ_\
M@,:/^&G?#G_0.U7_ ,!C0%CUC[ G]]_SH^P)_??\Z\G_ .&G?#G_ $#M5_\
M 8T?\-.^'/\ H':K_P" QH"QZQ]@3^^_YT?8$_OO^=>3_P##3OAS_H&ZK_X#
M&C_AIWPY_P! [5?_  &- 6/6/L"?WW_.C[ G]]_SKR?_ (:=\.?] W5?_ 8T
M?\-.^'/^@;JO_@,: L>L?8$_OO\ G1]@3^^_YUY/_P -.^'/^@;JO_@,:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7M%>+Z/_ ,G)ZM_UY+_(5[12&%-;M]:=36[?6@!U%%% !1110 4444 %%%%
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M0H^TPG_ELG_?0H FHJ'[1#_SV3_OH4?:8?\ GLG_ 'T* )J*A^TP_P#/9/\
MOH4?:8?^>R?]]"@":BH?M,)_Y;)_WT*/M$7_ #V3_OH4 345#]HB_P">R?\
M?0H^TP_\]D_[Z% $U%0_:8?^>R?]]"C[3#_SV3_OH4 345#]IA_Y[)_WT*/M
M,7_/9/\ OH4 345#]HB_Y[)_WT*/M,/_ #V3_OH4 345#]IA_P">R?\ ?0H^
MTP_\]D_[Z% $U%0BXBQ_KD_[Z%'VF+_GLG_?0H FHJ'[3#_SV3_OH4?:8?\
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M+?\ HH,OYT?\*C\6_P#109?SH ]9T/P_I_AK38M/TNVCL[.+[D,? 6N5\7_
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M(RM)=D@PY^<?E7T/3=O- 'D(_9OTKMXCU_\ \##2_P##-VE_]#'K_P#X&?\
MUJ]="X.:=0!Y!_PS=I?_ $,>O_\ @9_]:C_AF[2_^ACU_P#\#/\ ZU>OT4 >
M0?\ #-VE_P#0QZ__ .!E>4?&_P"$4OA/5?!\6D>*-=B2]U%(;K==%MT9(R/:
MOK0MAJRM5T+3=>DMY;R!+EK9]\3$YV-ZT@/.&_9OTLN2/$6O@'M]L/%)_P ,
MW:7_ -#'K_\ X&5ZM#?0SN4BFBD=?O*C@D5.K;CTHN!Y%_PS=I?_ $,>O_\
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M!Y%_PS=I?_0QZ_\ ^!E'_#-VE_\ 0QZ__P"!G_UJ]?HH \@_X9NTO_H8]?\
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M0./I7TO.Z2H89=I5Q@J3UJCI5GIOAFS2RM5ALH,DK%O R2<G% 'G _9NTO\
MZ&/7_P#P,H_X9NTO_H8]?_\  S_ZU>MB7(!QG-/!S0!Y#_PS=I?_ $,>O_\
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M@!*6BBE8 HHHI@%%%% !36[?6G4UNWUH =1110 4444 %%%% !1110 4444
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MWB[X>>"_%VJV6H>;>:3XHC;4I$'%Q:^8=Q/H<5]%?#3QWJOQ/^,6JZG87?\
MQ2.GV:(L0.1)(X!!_"J<=="?AW.O^)_QZ\*?":]L;+7;F5+N]_U,,*%F;\!5
M7P+^T=X-\?ZXNCV-[);:G(/W5M=H8VD_W0>M>&_M0ZAJ>E?M&?#JXTG0(?$=
M[AMMG-C!]^:Y[1=>O_C;^T#IBZIX9M? =_X,9[V2%<+/>+@\+C!(J(:K4IJQ
M]Q G\32Y..M?GG<_'WQEX\U7Q1KUCJ&L6USI6H/:V&F6=FSPR!>FYAQS7J%A
MXV\<_'_Q9I'AJ+5)?!366F+=ZB%3,DDI' QQCFG8EZ'U#XG\7V'A""VEU&5H
MTN)5ACP,Y8]*V89 \:N#PXR,U\*Z?X\\:V.A:GI_B#5H-8O=.\16]I%</'D>
M66].QIWC+XA^+['XEZC_ ,)+XEOO"EM#+"-+E2W+6;I@9WL.!1OH).^I]J_\
M)3IK>(3HBWB'5%C\XVP/S;/6M7)KXFNO#VH7/[36I^)[/Q3)+)%X7>[0PC,4
MI '3G&,U?^&.I>.F^!EUX\U;QU%'?WK-%']I^6*W3>1QSR<4NEV4]['V,\FT
M,Q;"KR3G@5RES\5O#L&DQ:DE^MQ9R7?V(2Q?,!+G&W\Z^0/"'Q)UK3OBOI7A
M:S\9W?B/3-=LIQ=2S0E%C<*<,A-87PYT[5/AM\%4OH=7.IK<>,GA,5U'N" 2
M\D9[FM%'N).[L?H4KEP"#C(R*4 ^OUKY!TN[\>?'2X\5^(]/\7-X;L]#D,-E
M91IN#%!DE^1UQ7.Z=\4/'OQKUWX?Z;8Z\?#ZWR30ZC)$NXN8V*[E^N*BPS[A
MP<YSBGU\\?LT>*?$B>*/&O@WQ!JG]MC1;K;;7S##,F.A%?0PZ4VN40M%%% P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *:W;ZTZFMV^M #J3-)G -<W
MX5^(6@>-[G4H-#U2#4)M.E\B[CB;)A?T-*X'345AZ/XNTO7]1U2PL+Z.YN],
ME$%Y$AR8G(R ?PK7#'US1<"3.:6L_4]8M-%M!<W]U':0%E3S)6 &XG 'XU<5
ML@'/7D47 ?2UC^(/$NG^%K,7>IW(M;8N(P[]-QZ"M&*83PI(C95@&5AW!I@3
MTG>L8^*M,'B0:!]M3^U_(^U"TS\_EYQN_.M3<V#R:2=P)J*QM1\3Z=I>HP6-
MS>QQ7<T;2I$3\Q11EFQZ 5YP_P"U5\-%EE1?$L,GEN8V9%) 8'!&<47N!Z_2
MUD^'/$%EXIT>#4]-N!<64XW1RXQD5IC.,9S0] W'T4PG!YXII9J )*,UFVNN
M6=_?7-G;W<<MS;8\Z)#DQYZ9JY++Y4;.QPJC)/M1<":EK,T+7;'Q%8B\L+E+
MFW+%-Z'(W X(K2SFBX"T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!#S7DFJ_ BUU;XF>)/%=Q=ETUG1_P"R6MBO"#GYQ[\UZY3=@I6UN!\TZ!^Q
MS;:#\'5\#)KDL\@U9-2.H.OSE5?<(_H*U/%'[->L1>*=4U?P3XME\,C6HDAU
M.V6,,K[1C<N>AZU]!;!G-!046 \'TG]EG2_#]UX'DT_4)$7PY.UU)N7YKF5C
MEF/U-6_$/[.-GXF\1^.=2N-1=$\368M2@7_5$8PP_$5[9Y8/)'-'EKZ55WL-
M.QX7X!_9XO?#/B+POK6JZZ=2N]#M39H0F/,3MFFZE^S.UY+XQN;3Q%<Z9?:[
M=+=17-N,- RG('N*]W\L"@(!4O4+GA7PL_9TNO#'Q ?QQXGUA-8\1>2;:*2&
M$1*$QC)QU)KH/C=\"[?XLC3-0M=5N- \1Z3()+'4[?DQ^JD=P:]5V"C8#2E=
MB/ _#/[.VNZCXML/$/Q \62>*+G3%86%L8@D<+D8\SCO2:%^R]%HB^&!_:S2
MG1=9?5@2O^L+9^7]:]]VBCRU]*;NP/(/$W[/FF^+O'7B77=2N#+:ZWI2Z;):
MX^Y@Y#CW[UR7AC]EG4Q?Z7;>+?%UQXA\.:/&\-AINW8&0C'[PCKBOHS8HHV"
MA*V@GJ?-NF_LP>)?#MRVEZ+XYDT_PB;HW2V:VZ^9&"<F,'TKWK4_#-GK/AF;
M0[Y#<V,]O]FE#=77&*V-BFEVBC=68^MSYBM/V6_&F@:=/X7T/XD7=IX+F9P+
M1X@TD4;'+(&].<5TFO\ [,5O%;?#Y/"VIMHTGA";S(B5W"=3]X'ZY/YU[P4!
MH\L4 ?,GB']D?5+ZX\4Z=I/C*?2?"WB.5KN[L$B!(F(^;!]#6OJG[,EYIT?A
MC4/"'B.30/$.CZ>FF2W21AENH0,?,#WYKZ#,8- 1<YQ0]@NSY</PHA_9[^"G
MC&QU.^O?%MSXCF<2.D67:67/;T!KT+]EGX6R_"CX1Z9IET&-_,3/,\@^?#<J
MI^@XKUV6SAG $D:RJ#D!QD ^M2[ :J[UN%CS+Q7\(%\2?%;PYXS^W-"^D*5^
MSXXDS69\4_@'!XZ\?>'?&>FWQTC7=(<AY8U_X^8B,&-_;DUZ^8U;K2^6#4):
M6[!U/G*;]F/7]#US4_\ A$?&+:'H>K3FYNK/R Q20_>*D^M>>_'71-8^'7Q$
MT+4-(FU+3I([(VTVMV\'F"Y.,8<>M?9_EBHKFQM[Q EQ#'.@.0LBA@#^-/>P
MSXX^ O[.6L>)/ >H3^(+NZM9KW5TU&.6Z3$L@4YY'8&N[\:?LLZWXFU&_M(_
M%[MX8U)D:XL+J$2F+;VC)Z9KZ06)54 #:H& !QBEV"GUN0E96/ ]2_9D-GX@
MTN_\.ZW)IUK;Z8VE3V[+N\V(CDYIVK?LM6>K? JV^'<FJR1_99OM$5V%S\X;
M<,CN*]Z\L8HV#GWJ;%>9\U^'?V4M3@\;>'_%.M^)(KJ\TI&B6VMK98HRI&,\
M=ZDMOV3[F*PN=(D\1--HO]L#6((3'RC%MS+7TAL'I1L%7=@E8^=-?_9AUB+6
M]6D\)>,)O#^CZT5.HV:Q!@2!R5/;-=#X;_9NTOPCXG\*:CIMTT-MH4+1B$K_
M *UF.68GW/->T^6OI08U/K0FT!YQX ^$<?@GQSXH\1K>&=M:E\PPD8$=>DTF
MP8IU#=P>NH4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK=OK3J
M:W;ZT ,9OD)'H:_-3X*OJ?P-\7>*?B]ITL]UX:O/$<NG>)-/4EA$AD(6X ]%
MK]+&3<#CT(KQWX4_L^6/@7PKXLT'5735M/\ $%[-<S0R#(VN2=OX9J5H[KL"
M.%_94N[34_C-\>-0L9UNK*[UNWFBE1MRLI@!!%;WQ]\5^)[3Q9IVD:=XCL?"
MFB20&2:_F;,SOGA54<XIW[*_[,$?[,Z^-+>'5YM6L];U/[=;^>27A3& F?:E
M^*/[.U[XL^+MIX^TRZMKFX6S6Q>QU,%X8E!SO1>F[FG)NZL*.[N?,/Q"^)GB
MSXY_LQ:Q'+K:07_ASQG;Z5_:$(*B[02@(_KQFON36KW4?"'PDO;J6Z^UZIIV
ME-(;G'WY%CSN_,5XA8?L;3:?\+O&OA@:V'NM<UM->@N ,+%.K!@N/[N17O-]
MX9U#7_AK<:'J<\9U*ZT]K2>>(84L5VEA3EU2'V/D"'Q_X^UC]GG3O'?BN^L]
M274]2C2/3MIV0IOP&SZ]ZU?B#\;/&=G\2=1T>77(/!=G816IT?[3$Q@O0R*6
M+,!@#)Q7J\O[,[2? G1?A[_:7S:?=)<?:,?>VMG%5OB%^SOXA\4'5-,BUBTO
M_#VK1112V^I1;GM-JA28F'(SUIO3;N&Z/%_CO\>H_@E^T!H?B6ZA_M76-4\'
MI9VQL_FA\]Y1B0GLN3UKZ\^$EEKMIX%TO_A)-2BU76)T\Z:X@_U?S<@+[ &O
M,M*_9+T*QU?3EO9/[4T>S\-'P^L5V-\G+[O,!/0@]*[WX(^ -4^%O@B#PUJ6
MJ'6(K"1DLKF3)D\G.55CW(J4]+">K3/&/!6K2_$;XH?&;Q+=-^[TBRDT6R1N
MD.U#O8>YSS7D'[,OC:QT?X11VTOPCNO$;)J-SF_2)6$QWGG)YKWWPWX N/!/
MQN\<Z*(9?^$=\9V9G@N%'$=R01(":J_#;X+_ !6^$GA8>'-!U_2WTV.XEFB:
M>(LX#MG!HCY^13-37OB/JGP^^)_PYC:S72? VO6;VTMHPVFVNSRBGMTS7E/C
M+]JSQ3X?\(ZIK8E2&W\0>(QH^@S,A988ER'<@=>0>E>Y?%;X*ZI\9/@\/#NN
M:G':^)(I!<0:E;# AE'1E_#-4/$W[+NEZS\+?"7AFUNC;7_AF5;RQO&&0;C^
M)F'<$Y-+O<--#R?P#^T7XGL=<\0^'9M0?Q+;+H\M];:NL#(L$ZJ3L8L!QQ5'
M0_BK\6_#OPX^'WQ-US5[._L=9NH;:[TJ-3PDLA16'N*]OTCX/^*-0MM:_P"$
MDU:RS>6#V,<&GP!$!8$;V]^:K:M^SD^H_!'PAX"&H[6T*>WF^T?W_*DWX_&M
M-!'AO@\^-O 7Q6_:#\1Z3J']M3V<4<MOIIR<DY*X'M[5W'[-GQ5\0>+_ !18
MPW_BZSU:&[M#)?Z5.K1W%M,?X5! R!7<W'[/FJP?$#QIJ^E:^VFZ?XHMT$WE
M_P"MAF0?*0?2LGPQ^S3J'_"QM$\9^*;^UDOO#\+)!)IJ&-KD>LOKTJ(Z6OLB
MI.Z=@^"&K-X5_: ^)7@6-F_LM6CU"RA)XAW+EP/J3FOHQ3\M>#_ CPC>:K\2
M?'7Q%U*U:U.K3BVL8I.&6&/Y2?Q(KW@ #I1;1$]6/'2EI!TH#9I@+12$X/2E
MH ***0\4 +12 YHW"@!:*:6H#9Q[T .HHHH ***:6Q0 ZBBB@ HHHH **0G%
M!;!H 6BFA\CI3J "BBB@ HHINZ@!U%(#FEH **** "BDSU]J3=[4 .HI <]L
M4M !1110 444A.* %HHHH **** "BF[J-_&<4 .HI V32T %%%% !12$X% 8
M&@!:*** "BBD)P* %HIN_GH:-U #J*0?E2T %%%% !12;L'%&10 M%%% !11
M10 4444 %-;M]:=36[?6@!<<8I#&"<TZB@!OECWH" 4ZBE8!H0?6EVBEHHL
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M%O&TLC'LH&35H]*\R_:1>^C^"'BTZ=N^U"R;&WKCO^F:F3**OA#XWQ:M\/\
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MH[VY(QO7U%*&JU!Z'T7124M4 4444 %%%% !36[?6G4UNWUH =1110 4444
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MK$\,>$M.\(6;VNFVZPQR.9'8=78]2:W*$]$@ZA2'I2T4P*6H(TFGW"(,NT;
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M% !1110 4UNWUIU-;M]: '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH
M7'.:6F[Q1O% #J*;O%&\4 .HIN\4;Q0 ZBF[Q1O% #J*;O%&\4 .HIN\4;Q0
M ZBF[Q1O% #J*;O%&\4 .HIN\4;Q0 ZBF[Q1O% #J2DWBC>* '44W>*-XH =
M13=XHWB@!U%-WBC>* '4@&*3>*-XH 6EIN\4;Q0 ZBF[Q1O% #J*;O%&\4 .
MI#2;Q1O% "TM-WBC>* '44W>*-XH =2$9I-XHWB@!U%-WBC>* '44W>*-XH
M6EIN\4;Q0 ZBF[Q1O% "XP:6F[Q1O% #J2DWBC>* %I:;O%&\4 .HIN\4;Q0
M ZBF[Q1O% #J*;O%&\4 .HIN\4;Q0 ZD[TF\4;Q0 ZBF[Q1O% #J*;O%&\4
M.HIN\4;Q0 ZBF[Q1O% #J*;O%&\4 .HIN\4;Q0 ZFN< ?6C>.U-+Y(X[T ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b4_004.jpg
<TEXT>
begin 644 form424b4_004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #' PP# 2(  A$! Q$!_\0
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MO_/*;\A_C0%C;HK$_P"$JM?^>4WY#_&C_A*K7_GE-^0_QH"QMT5B?\)5:_\
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M[:N)T;_D*VW^]_0UVU!+*6K27\5F6TV"WN+K(Q'=3-$F._S!6/Z5B_;?&/\
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M% 79YO\ V#XR_P"@=H?_ (,9O_C%']@^,O\ H':'_P"#&;_XQ7I%% 79YO\
MV#XR_P"@=H?_ (,9O_C%']@^,O\ H':'_P"#&;_XQ7I%% 79YO\ V#XR_P"@
M=H?_ (,9O_C%<\FC^+C\1IU_L_1/,&CQC']H2XQY[G.?)KVFN5C_ .2HW/\
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M,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%%
M79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%% 79YO_8/C+_H'
M:'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1
M_8/C+_H':'_X,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X
M,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%%
M79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%% 79YO_8/C+_H'
M:'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1
M_8/C+_H':'_X,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X
M,9O_ (Q7I%% 79YO_8/C+_H':'_X,9O_ (Q1_8/C+_H':'_X,9O_ (Q7I%%
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M%=^&;;B@#TOQ-^T/X+\.65K>Q:B-=L;G3]2U*.[T5X[J(QV,2RW"[E;&_:P
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M3EC\3LM%Y>>F_KY'G2:SJ$6\IJ%VA=M[;9V&X^IYY/ Y]J?_ &_JG_03O?\
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M_ E_\:7^W]4_Z"=[_P"!+_XU0HH^NXG_ )^R^]A["E_(ON1?_M_5/^@G>_\
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M!OPUXSU+P9=7]M)'#X2O?[0TRPM6$5JLP0HC-&!@A 25' !K3VM"Z]S^M?\
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M@"UX4CUZ+0K9?$L^GW.M?,9Y-*A>*W/S':$5V9N%P"2>2">,XK8HHH ****
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M=JS=W<SC'(HVM..G][TWUUV5K[6':Q\4FU.RU&.'1K:SN=4:-M0G61F$^S'
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MA7(]LU[9XA\074OC/P/8WUXS:9=6MO/<0R$;)),DAF_X$%JQK,-S=:<\?BW
MC/B1%M#< #]QN'W?]C&:W?!V'FZL:-=^X[7<4E?E4O>?,[)II+N[F:S^K'D=
M2FK2UT>MKM:::O37R/#&M)DA69H94A;I*R$*?H>E)+:S0*K2PR1*_P!UG0J&
M^F>M>]^+[2*^F-QJ;7VGV5IK%O"EK=R*;6YCW !HU &  ?T.:H^/QJ)\,^,O
M[9#?9UU"'^R/- QCC_5^V/ZU6*X)IX>-:7M6^1-KW>RDVY:WBGRV7=^1-#B&
M5:4(^S2YG9Z]VEIIJU>[\CQ Q.(U<JP1ONL0<'Z'O3Y+.>%%>2"6-&^ZSH0&
M^A/6O4?B39ZQ>> _"5U=:<\$\'F_:$C@\M8B6 0%1P,\5I^)(?$VF_#6^775
MN-4OKUEG&$!CTZ-"#DL. >.@Z5YSX4C&K7A)SM3IQFGR::QO9ZW3OHK7ZMVL
MSK6=.4*4DHWE)QMS=G:ZT[:ZVZ6W/''L+J-2S6TZ*.2S1, ![G%(]G<11"62
M":.(])&C(4_CBO5=<\2:OHGPVCMM6OYKS6->Y2*<@_9[?UQC@M_7VK6*ZY+\
M//$<.NB]MKP6ZAI=1"&UQG@0A>AQC\<5O'A7"U9RI4ZL^94^=WBO==G)1D^:
MR;23^?D9O.JT(J<X1LY<NDGJKI-I6U2?]:GB*PNZ.ZH[(GWF"DA?J>U,KW.V
ML]&3X<^(M+TC6-/EL(K2-I+@;MYE)RSR''? "@=,5X9VKYK/,E_L>-!^T4_:
M1N[6:33::33=UIOU/6R[,/K[J>ZX\KMK>]K7N^WH%%%%?*GM!5C3[^XTJ]AN
M[29K>YA;='(AP5-5Z*NG4G2FITW9K9HF45-.,E=,^GOAC\3;?QQ9"WN-MOK$
M*_O80<"0?WT]O4=JTXO^2HW/_8&B_P#1\E?+.DW%[::G:RZ<TJWRR#R##RY;
ML ._TKZ5\,RZC+XUC?5HHX=2.A0F=(CE0WGR5_67 W$U?/L-*CBH/VE.UY6T
MEZ_WNZZ[GXKQ%E%/+:JJ47[L^G5?\#_ACNZ***_4#Y **** "BBB@ KEO'7_
M !\>&/\ L,P_^BY*ZFN6\=?\?'AC_L,P_P#HN2@#J:*** "BBB@ HHHH *Y+
MX>7,5GX%CGGD6*&*6[=Y'. JB>4DD^@%=;7&^!M.@UCX>-872>9;737D$J9Q
MN1IY58?D30!Q'A7]I[3O$-]X>FOO"VN^'O#'B;S!H/B/4EA%M?[8GF&Y%D,D
M/F11O)'YBKN53T.!72Z'^T1\-/$NC:MJVE^-=(O=.TJ.*:\N8K@%8DD.(F_V
M@Y!52N=Q&!D\5Y@O[.GC-/#'A[P]K'BJPUWPOX*MIFT&SM---O?7LJVDMM:"
MZE,A3]TDI'R*N]@K'&,'F-"_9&\4>-?AQH3>--<TZP\3:=H&B:;IMG864J6]
MK]AD2XV71$^^5FD&QC&Z!0N4P3F@#V_4OVE?A=HVF:=J%]XXTBTM-025[9YI
MMI=8G$<I*D97RV(#[@-O\6*Z_P 4^-=$\%:"VM:UJ$=EI8**+C#.&+D!0H4$
MMDD8P#7ANA_LJ7-GINL+/?:-I]UJOAO6=#GBTJSG,(FOY(F-P6GFDD=@(ANW
M-\Q/\.,5VWQ.^$6N>+OA/H/A71/$*:9=Z9)9M,TPF6WU&*%=KP3>3(DBQOPQ
MVN#E0#D$@@%JP_:/\!:KX]T'PG8ZW'>7^N:9_:NG7%N-]O<1>:8MH<='W*WR
MD#&TYP1BJWBW]HSP]X+^+#> =1LM1743H<FM0WJ1J;:;8)6^S!MV1,4@E< @
M A&YXQ7)?"/]F[7_ (0ZMX.O+#Q!I-S'IUGJ.G:I;'3Y4CE@N=0>]4VW[TF-
MD9]GSEP5YZUI_&/]FS_A;-[XRNQKITB\U?1K*RTR[B@W2Z9>6LMQ)'<@Y^8?
MZ1M*\97>"<-0!U6F?M!^!;V+P\ESK]KINI:WI]OJ5OIUTX$R)-%YL:/C(5RN
M<*3EMIVYKB-/_;:^&-_8^%-4?5OL&A>(+.[NDU&^'E+;/;^26AD7D[RLX;Y<
M@!&)-<_I'['L^A^-=+U5=1T?5M/QI$E]%J=M=&6.>PMXH%DMA'<+&-P@1E\U
M'*-DC=G V_!O[->N:)I_AVQU;Q'IU]!X=T35O#]@]O8/&\MM=" 1O+ND8>8@
MA.[;@-NXQ0!ZE<?&'P3;>)M-\/2>)].&L:DD<EI;+,&\T2 M%AA\H+@$H"06
MQ\N:Y:/]I[P'J7B31=+T36[37X+]KM;C4-/N%DAL?(MWG;S2/5488'((YKSC
MPS^QS-X5\8:+J2:EI&LV$0T>6]CU2VNC*EQ86\,"R6XCN%B&X0(R^8CE&R06
M& -T_LO:G;?#WP'X?TWQ>=(U'PMIVJ6D>K6=IMD,MW;21+.@W?*R-)OZDG'4
M'F@#O3^T7\-4\-MKTGC'3(=*6\73VFF<H1<LAD6'8P#;V0%E7&6'(S65\0OV
MI?AW\/\ P%!XH?Q#9:K!>V$FH:9:V4X>34(TP#Y>.@W$+N; #'!(-<#\-OV2
M]4\):];:SJ6MZ6;E?$-CKLEMIUK<&,_9["XM2N^XGDD9V,X<NS?PXQWK/U3]
MC_Q-;Z)J>F^'_&&E6B:[I-YHNJR:AI3S%8);^YNT:WVRKL8?:G1@V5.%; (Q
M0![YI?Q9\(ZQXPG\*6FO6D_B2!6,VG(^YXRJAG0G&W<H925SD9&0*YCQ+\=9
M=/\ &&L^'_#G@K7O&T^@B$ZS/I)MTCLVE02)$OG2H9I?+*N43. RY.6 K'\(
M? C7/"_QOU'QC#KUIIN@W<ES/<:-I,=Q&NI2RJBK)=1O,\(D3;GS8HT9S][N
M#9U3X4^.= \>>*-=\ ^*='TNR\52P76I6>MZ7)=FVN8X4@,]NR31\M''&"C@
MC<@(/)% '5#XX^!/[5UG3)/$UC;7^CV\UU?P7#&(P10C,SDL "(\C<5)VYYQ
M52R_:)^&FH^&M0\06WC72)]'T^XCM;FZ2?(260 QH!U8N""NT'=_#FO%M7_8
MW\1^(_%?B#5=6\:6=\;ZPUVP@O9K6XDO&348BB++NG,2I "%5(D0,JC.#78^
M)OV;-5O/%Q\5Z)K]C::W9SZ3=Z?%>V!EM?,L[:ZMW695=25=+MMI4@H54C/2
M@#T&'X[?#^XO]#LHO%NFR7.MQQRV"++GSED8K'ST4NP*J&P6((&2,5H^#/BI
MX2^(_P#:(\*:_8>(7T\A+D6$PD$3G< K$< Y5ACMCFO%]1_99UG6?B2GB_5=
M2\/:O<ZF^FW&M6]U8W:Q)<69^1[2-+I5 ("D"82;77=DY*UZ[\(/A[)\*_AK
MI/A?[7'?36"RYNEB\M9&>5Y,E<G^_P \\XS0!R&@_M4^#9?!MOXA\5SCP%%=
M7U]86MKK5Q$9KAK24Q3L@B9\JKJWO@;NG-=-J_Q[\ :-J L)O%%A)?M9?;TM
MX)/-9X3$TRD%<C+1J64$Y8#(R*\^\ ?LXZ[X>/A^76]?TR]GTE_$+#[#8O&D
M@U299NCR,08VWC_:4CISG'\*_LH:YX7\1^%)[3Q19Z;IVF:59:9J<VE07$%U
MK$=O9?9?*N$,YMW4G#*YC\Q JJ&XS0!T,_[97P]A\$0>,%N9Y?#LFEPZFTR!
M?.C$D\4(B,);?N#3+E@"HP1N)QGTFQ^+7@[4[#[9;>(K&2W^TV]F7\S&)IU5
MH8R#R&<.I /)W"O$&_9/\2ZIX.ATG5?%VF_;K#PJGA>PNK/375-D%U!/;32H
MTIR?]'"NJD [CMQ6I??L\^-M6\;KJ]UXIT*+3K_7-'\2:O:0:7*96O+%8D,=
MNYFPD3B%#\P9@<C)!X .K\+?M7?#+Q3X"M?%Z>(XM/TFXG>V47J,DHD3<678
M 2<*I8D9 7DD5ZO8WUOJ=E;WEG/%=6EQ&LL,\+ATD1AE65AP000017R[>_L@
M^(9M#\,VG_"0Z-?R^%9M2M]*2[M;N**XL;Q@[K<>3<(_G*54!D8*0""O.1]&
M>!?#,?@OP7H6@0Q6L,6F64-FL=C$T4"A$"XC1F8JG' +$@8Y- &[1110 444
M4 %%%% !1110 4444 %?/O[;WQ ^(/PY^ WBC5? 6D)<31:9=2W6LC4UM9]*
M"J"DT49C;SFY;Y<KT]Z^@J9)$DT;)(JNC#!5AD'\* . ^&NO^)/$OPR^V_$#
M0K?PG>M"PFAM=5^V*;?RP?.\Y43:2"QP!E<=:^,_@W\5M2\._#*^D\#^+9;_
M %[5?B9!X=^U:U//JBV^ERRR):NL<C\ KDA@06QR:_0PH"NT@;>F,<5 FG6L
M8PEM"@R&^6,#D=#712JJFFFKWL93@Y--,^*O!7[1OQ8'B/P['K>L:3J6GW>M
M>(?#DT,&D&!WDL(9)([K?O.-Q4#8 !CU)S7+0?M,_'"3P0=8/B?0O-F^'W_"
M<H#X?.8S'/Y36H_>8._J7(X[ =:_0#[' ""(8\@EA\@ZGJ?QH^PV^W;Y$6W;
MLQL'W?3Z>U:^WA_S[1'LY?S'Q9\1/VQ?$_A;4O%VG"_T_3]6,?ABYT"QEL6=
MIHKL1F^(/\87<0"2-OO6C)^T'\3K;XHR/_:6FW/A>/XDR^"AHHTS;/) 8/,2
M3S]WW@>!\O/<GI7V$]C;R,&>")F"[0S("<9R!],TOV2'.?*CSNWYV#[WK]?>
MI]M37V!^SE_,? =E^TO\4/B)X<UO3H->M9M4U3PMKE_?Z7I6E/#=^$KBV)$,
M3/NW,T@!0%L,&(9>G.;#X^\:ZG>?#77O#?Q&@U36+3X<:MJ$VIR6)GA+P"%V
MMI(O,VM,I&PRMEL[CC)K]#H[2&&262.*-))3EW50"Y]SWID>GVT2A4MX4 !&
M%C X/4?C5_68K:"_KY"]DWO(^$==_;%^)TFO^'1 VA>';>;1-&U6.WU8)##J
MYN55KD([G><$E%6++ CYLYKJ]8_:!^(^F>$OBKXPO_$-I9>'_#_B6Y\.:=:6
M.AK-=QN+F%8Y9)))%CV!792S  9W$G %?8CV%M)Y6^WB;R>8]R [/IZ?A3C9
MP-')&T,;1R9+H4&&SUR.]2ZU/2T$'LY?S'P=IG[7/C^Y\(>'SJGBO0M",WC:
M]\.WOB66P2>W%G':"9)MJN$+;FQN4A3Q^-BX_:U^+>@_#CP3XCN]/MM2?QA8
MW^BZ5Y6G&(2:PMSLL;HJ3D131'=LZ?*2.#7V-XF^&7AKQ?JGA_4-6TN.ZNM!
MNVOM/;<R+#,T9C+%5(#?*Q&&!%.\3?#;P]XQUKPUJNL6 O+OPY=&]TS,CJD$
MQ39YFP$*Q )QN!QGC%7[>BVO<_K47LY_S&QH$%_;:'I\6JW*7FJ);QK=7$2;
M$EE"C>RKV!;) [5?I ,4M<!TGQGX(_:,CTK]FSP=8Z9XWTU?%DFH16&M:A?7
M"WEQHEK)>.DEW/$S9 3*)F3"J9%+<#%1WW[17Q7DT;0;3PW+IWB34O$5QJVA
MZ!JW]G[;6_N;.Y5X[UMK8$4MHMS]T[2\65.& K[$71[!#*5L;93,I23$*_.I
MZ@\<@^AJ=+:*)(D2-$2(8C55 "#&,#TXXH \-\!_%3Q?\4OV;?%?CW1+5EU;
M4K?4[KPM8/;;)HT1'2U213]YS)&6Y'.X#I7DNE^/_A_X'^&L'B7X>^-;C5/'
M\^EVW]K7&IZM=Z@]M%+<6\=W?W]FTA"/!YC/M94VX8<*"!]GI&L:A44(HZ!1
M@"H(].M(7G=+6%'N/]<RQ@&3_>XY_&@#XHU/XW>+EU=-=LM3A\<3^%[/Q7%I
M.KV,!2UUM8;;3Y$E:.([)/+>26,F/AC"VW!)KH=)^-'CSQ-KUAX3\/?$32]?
MLKSQ%;:=%X[LM'BD22.33+FZF@6-6\HR1O#%\P)P)0K L#GZX@LK>UCBCA@C
MACB&V-8T"A!Z #H*2WT^VM(TC@MXH8T8LJ1H%"D]2 .A.3^= 'SS??$CQSXF
M_8JU/Q5922'QL-.N8Y+K2;8K+F&X>&:>&+G$GEQO(JC/S8 SQ7$Z[\2/A?\
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M<+\I(ZU](U!%96\"HL<$4:Q\H%0#;QCCTXXJ:@!:*** "BBB@ HHHH ****
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M@4 ?5/\ 8/B[_H;+7_P4+_\ '*/[!\7?]#9:_P#@H7_XY7RWXS_:V\=>%/\
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M5_T'[W_OL?X4?\+*\5?]!^]_[['^%'_$4LL_Y\3_ /)?\P_U.Q?_ #\C^/\
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M1R?]@^+O^ALM?_!0O_QRC^P?%W_0V6O_ (*%_P#CE=910!R?]@^+O^ALM?\
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MY?[)4_\ +Q)G_EI7J-<M\,_^1.MO^OBZ_P#2B2@!G]@^+O\ H;+7_P %"_\
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MS^R=\0;WPU/8P_$.QN]0U?P[?>&M6N]:LI[UHK6:X>:(6[M,'8Q"1H@TS.6
M5B<C!Z7P[^RW<>&_C!)XF6[TC4M&EUI_$ 6_BNVO;6Z>#RF$.VX$&,YP[1%@
MK%>>" #8\<^._"WACQ5<_#W2/AFWC"^2SCU[4-*TRVL8HTB>1T279/)&)I"T
M3\(&(V\D9&>H'CGX9S>-[?2+B;1H/%UI;@1VUS;HMS B1B;RU8KP43YRBG(
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MS_IG9T445^O'PX4444 %%%% !7+>.O\ CX\,?]AF'_T7)74URWCK_CX\,?\
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MC4DG@?3_ /2]-&FFT"_8Y9VNE 5)-^[_ $<R-(JN&(;([*\_;.\/6MSX%?\
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M:-_9$MP?$FIP7;V\,-L!,&B$WEDD .4W$D[4)K>NOB?XQ\/?'A/#NL2)X/\
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M W@V%[KR].GC@N(Y8S;+=RB&,2C$FR/=M4D$\@5L?\)'XE_Z%!__  8PT?\
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ML3*3C\!7DG_"L/%?_0!N_P E_P :]N\+S^*M#CU19?"9<W6H3W:[-2AX5VR
M?>MK_A(_$O\ T*#_ /@QAKX#B#@W!\18F.)Q-247&/+I;:[?5/N?2Y9GU?*J
M3I4HIIN^M^R7?R/G;_A6'BO_ * -W^2_XT?\*P\5_P#0!N_R7_&OHG_A(_$O
M_0H/_P"#&&C_ (2/Q+_T*#_^#&&OE_\ B%N5_P#/ZI_Y+_D>Q_KCC/\ GW'\
M?\SYV_X5AXK_ .@#=_DO^-'_  K#Q7_T ;O\E_QKZ)_X2/Q+_P!"@_\ X,8:
M/^$C\2_]"@__ (,8:/\ B%N5_P#/ZI_Y+_D'^N.,_P"?<?Q_S/G;_A6'BO\
MZ -W^2_XT?\ "L/%?_0!N_R7_&OHG_A(_$O_ $*#_P#@QAH_X2/Q+_T*#_\
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M_!C#1_PD?B7_ *%!_P#P8PT =717*?\ "1^)?^A0?_P8PT?\)'XE_P"A0?\
M\&,- '5T5RG_  D?B7_H4'_\&,-'_"1^)?\ H4'_ /!C#0!U=%<I_P )'XE_
MZ%!__!C#1_PD?B7_ *%!_P#P8PT =717*?\ "1^)?^A0?_P8PT?\)'XE_P"A
M0?\ \&,- '5T5S%OX@\12W$22^%'AB9@'D.H1-L&>3@=<>E=/0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
